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1. ABSTRACT 
Alterations of CDKL5 give rise to several forms of neurological disorders generally 
characterised by epileptic encephalopathy, severe developmental delay, hypotonia and 
RTT-like features. To date no cure exists and only secondary symptoms can be treated. 
About 15% of CDKL5 patients carry a nonsense mutation and might benefit of a read-
through strategy as “personalised” medicine approach. The read-through process occurs 
when a near-cognate aminoacyl-tRNA binds a premature stop codon (PTC), allowing its 
suppression and the subsequent protein elongation. This mispairing event can rarely 
occur, but can be facilitated using a wide range of drugs. In order to test PTC suppression, 
we have chosen some human pathogenic CDKL5 nonsense mutations located in the two 
main domains of the protein:  the catalytic N-terminus (R59X, R134X) or the C-terminal 
tail (Q347X, E364X, R550X, S855X). We then evaluated the read-through process using 
aminoglycoside and non-aminoglycoside drugs in cells transfected with the mutagenized 
constructs. In this study, we have demonstrated that tested CDKL5 PTCs can be 
suppressed by gentamicin and geneticin (G418) in a dose-dependent manner and that PTC 
position can be critical for read-through. In particular, G418 was found to be more 
effective than gentamicin. Considering the known aminoglycosides toxicity, we 
evaluated the activity of PTC124 and GJ072 but no PTC suppression was detectable in 
our experimental conditions. Finally, in order to understand whether the full-length 
derivatives may maintain the proper function of WT CDKL5, we analysed some features 
of read-through products compared to the WT protein. In particular, while premature 
truncated proteins showed an altered subcellular localisation, read-through products 
demonstrated a nucleo-cytoplasmic distribution more similar to the WT one. Moreover, 
by evaluating the auto-phosphorylation of the TEY motif, the read-through derivatives 
demonstrated to recover some catalytic activity, although remaining highly hypomorphic. 
Nevertheless, preliminary studies on Cdkl5-null neurons transfected with R134X 
construct suggested that G418 treatment can ameliorate impaired neuronal morphology. 
Collectively, our results indicate that: (i) aminoglycosides are able to induce read-through 
of different CDKL5 PTCs; (ii) the read-through derivatives recover some features 
characterizing the WT protein; (iii) PTC position can be crucial for read-though and for 
rescue of a proper function and (iv) neuronal morphological defects might be rescued by 
small amount of a possible hypomorphic CDKL5, therefore supporting the potential 
validity of a read-through therapy.  
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2. INTRODUCTION 
 
2.1 Rett syndrome 
 
Rett syndrome (RTT OMIM 312750) is a severe childhood neurological disorder 
affecting principally girls. The disease has an incidence of 1:10000 [1] girls born alive, 
thus representing one of the main causes of severe intellectual disability in girls. 
First cases of girls affected by this syndrome were reported in German about fifty years 
ago (1966) by the physician Andreas Rett [2]. However, seventeen years later, RTT was 
recognized by the medical community thanks to the English work of Dr. Hagberg and his 
colleagues who described patients with a clinical phenotype well overlapping to the one 
described by Rett [3].  
In 1999, Huha Zhogbi’s laboratory identified MECP2 (Methyl-CpG binding Protein 2) 
as the main genetic cause of classical RTT, thus reporting the first neurodevelopmental 
disorder related to epigenetics [4].  
 
 
2.1.1 Clinical features of RTT 
 
Girls affected by typical RTT appear to be healthy until the first six-eighteen months of 
life, when a developmental arrest followed by a regression phase occurs.  
Consensus criteria for correct diagnosis of RTT were developed by Hagberg and 
collaborators [5] [6] and then revised in 2010 by the RettSearch Consortium, constituted 
by a group of physicians [7]. Revised diagnostic criteria include the core features which 
are fundamental to simplify the diagnosis of RTT or its variants (Table 1) [7]. 
The progression of clinical phenotypes can be divided in different phases.  
The stagnation phase is characterized by growth arrest, hypotonia, and in some case 
deceleration of head growth leading to microcephaly. During rapid regression phase, 
patients lose hands skills, ability to speech and autistic phenotypes appear, such as hand 
stereotypes, mental retardation together with motor abnormalities and seizures. With 
stationary phase, the loss of skills stops and patients may be subjected to scoliosis. The 
late motor deterioration is characterized by decrease or complete loss of mobility and the 
appearance of Parkinsonian features [6] [1]. In addition to the described clinical features, 
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RTT patients suffer of autonomic perturbation, including respiratory and gastrointestinal 
problems, cardiac abnormalities such as long Q-T intervals, tachycardia and sinus 
bradycardia.  
 
 
Table 1. Consensus criteria for RTT diagnosis (adapted from Neul et al., 2010 [7]) 
RTT Diagnostic Criteria 
 
Main Criteria 
 
1. Partial or complete loss of acquired purposeful hand skills. 
2. Partial or complete loss of acquired spoken language 
3. Gait abnormalities: Impaired (dyspraxic) or absence of ability. 
4. Stereotypic hand movements such as hand wringing/squeezing, clapping/tapping, 
mouthing and washing/rubbing automatisms 
 
 
Supportive Criteria for atypical RTT 
 
1.  Breathing disturbances when awake 
2. Bruxism when awake 
3. Impaired sleep pattern 
4. Abnormal muscle tone 
5. Peripheral vasomotor disturbances 
6. Scoliosis/kyphosis 
7. Growth retardation 
8. Small cold hands and feet 
9. Inappropriate laughing/screaming spells 
10. Diminished response to pain 
11. Intense eye communication - “eye pointing” 
 
 
Exclusion Criteria for typical RTT 
 
1.  Brain injury secondary to trauma (peri- or postnatally), neurometabolic disease, or severe 
infection that causes neurological problems 
2. Grossly abnormal psychomotor development in first 6 months of life 
 
 
Required for typical or classic RTT 
 
1. A period of regression followed by recovery or stabilization 
2. All main criteria and all exclusion criteria 
3. Supportive criteria are not required, although often present in typical RTT 
 
 
Required for atypical or variant RTT 
 
1. A period of regression followed by recovery or stabilization 
2. At least 2 out of the 4 main criteria 
3. 5 out of 11 supportive criteria 
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As the patients get older, their conditions reach a plateau and some of them survive up to 
sixty-seventy years of age [1]. 
Beyond classical RTT, atypical patients have been described, having milder or more 
severe phenotypes.  Atypical variants of RTT can be organised in three main classes: the 
preserved speech variant (a.k.a Zappella variant), the early seizure variant (a.k.a 
Hanefeld variant), the congenital variant (a.k.a Rolando variant). The Zappella variant is 
characterized by moderate intellectual disability, milder reduction of hand skills, the 
capability to say single words or phrases while epilepsy is a rare event. More severe are 
the Hanefeld and the Rolando variants; the former entails often intractable seizures before 
the first sixth month of age, while the second implies grossly abnormal initial 
development including severe psychomotor delay and inability to walk together with the 
lack of the typical intense RTT eye gaze [7]. 
Whereas  more than 95% of patients affected by classical RTT presents alterations in the 
MECP2 gene [1], only 30-40% of variant patients exhibits mutation in this locus. In 
particular, such mutations are mainly found in the  preserved speech variant, while 
different causative genes are often associated with other variants: CDKL5 with the early 
seizure variant, and FOXG1 with the congenital form [7].  
 
2.1.2 MeCP2 structure and functions 
 
MECP2 is a complex gene located at X chromosome (Xq28) consisting of four exons that 
can be alternatively spliced in two isoforms: MeCP2-e1 and MeCP2-e2. Moreover, the 
presence of a 3’-untraslated region containing multiple polyadenylation sites permits the 
generation of four different transcripts [1] [8].  
MeCP2 is a nuclear protein isolated in 1992 by Adrian Bird’s laboratory for its capability 
to bind methylated DNA [9]. It is composed by five main structural domains: the N-
terminal domain (NTD), the methyl-binding domain (MBD), the intervening domain 
(ID), the transcriptional repression domain (TRD), and the C-terminal domain (CTD, Fig. 
1) [8]. Although all domains with the exception of the N-terminal have crucial roles for 
MeCP2 functions, only the MBD and TRD functions have been clearly elucidated. In 
particular, the MBD is necessary for specific binding to methylated DNA, while the TRD 
is crucial for the recruitment on methylated DNA of transcriptional corepressors such as 
Sin3A, NCoR and ATRX. 
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MeCP2 is a multifunctional protein involved mainly in transcription regulation. Although 
it is still under discussion its capacity to activate transcription and the possible relevance 
of this activity in MECP2-related disorders, in well accordance with its capability to bind 
methylated DNA, MeCP2 is mainly considered a transcriptional repressor [8]. 
Additional studies have identified MeCP2 as a global regulator of chromatin. It has in 
fact been demonstrated that in mature neurons, where the protein reaches its maximal 
abundance, there is one molecule of Mecp2 every two nucleosomes. In these cells, Mecp2 
is proposed to substitute itself to histone H1, therefore functioning as a linker histone 
[10]. According to this structural role, it has been demonstrated that the absence of Mecp2 
leads to an increase of H3 acetylation and H1 levels [11]. 
Beyond regulation of gene expression and influence on chromatin structure roles, 
additional functions of MeCP2 have been demonstrated. In particular, different studies 
have proposed a direct or indirect effect on protein synthesis; indeed, a reduction in the 
AKT/mTOR signalling pathway in the absence of Mecp2 has been found in mouse brain 
and human cells [12] [13]. Furthermore, a role of MeCP2 in mRNA splicing [14] and 
miRNA maturation [15] has been proposed. Whereas all these studies suggest an 
involvement of this protein in gene expression, a recent publication suggests that a 
subfraction of MeCP2 colocalises with the centrosome where it affects cell proliferation 
and microtubule nucleation [16].  
 
 
Figure 1. MeCP2 protein structure. 
Schematic representation of MeCP2 protein illustrating the different domains. Adapted from Bellini et al., 
2014 [8]. 
 
Alterations of MECP2 are in most cases de novo and comprise missense, nonsense and 
frameshift mutations. Among them, eight hot-spot mutations exist accounting for 65% of 
all MECP2 mutations and consisting in C to T transitions (R106W, R133C, T158M, 
R168X, R255X, R270X, R294X, R306C). Moreover, although missense mutations can 
be distributed along the whole open reading frame, most of them falls in the MBD, while 
deletions/insertions occur mostly in the CTD [17]. Alterations of MECP2 have also been 
associated with other forms of intellectual disability, including autism, mental retardation, 
schizophrenia and Angelman-like syndrome; moreover duplication of  Xq28 region gives 
rise to MECP2 duplication syndrome in males [18]. These observations indicate the 
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crucial role of MeCP2 in the brain. Indeed, while MeCP2 is a ubiquitously expressed 
protein, its highest levels are reached in the Central Nervous System (CNS, MeCP2 e-1 
isoform) and, particularly, in neurons. MeCP2 expression is low in immature neurons but 
it increases during maturation reaching the maximal abundance in mature neurons [19] 
[20]. Such expression profile suggests MeCP2 involvement in neuronal maturation and 
dendritic arborisation [21]. Indeed, the overall structure of RTT brains is generally 
maintained but they are characterized by a reduction in size and weight, with smaller, less 
arborized and more compacted neurons. Furthermore, Mecp2-mutant mouse models 
exhibit evident defects in dendritic spines and morphology [22] and such observations 
have been confirmed by studies in post-mortem RTT brains [23]. Morphological 
impairments are also associated with defects in synaptic connectivity due to decrease of 
excitatory synapse number [23] [24] and imbalance between excitation and inhibition 
[25]. Moreover, Mecp2 loss of function causes alterations in spontaneous synaptic 
transmission and short- and long-term synaptic plasticity, such as LTP and LTD that are 
well correlated with learning and memory deficits of RTT patients [26] [27] [28]. 
 
2.2 CDKL5-related pathologies 
 
As already mentioned, beside classic RTT, atypical variants lacking MECP2 mutations 
exist.  
The first case of atypical early-onset seizure variant of RTT was identified in 1985 by 
Hanefeld who described a girl with infantile spasms and hypsarrhythmia sharing clinical 
characteristics with RTT patients [29]. This RTT variant, also known as Hanefeld variant, 
presents a phenotype overlapping to West syndrome (or Infantile Spasm Syndrome, X-
linked, ISSX, OMIM: 308350) whose clinical outcomes comprise the triad of infantile 
spasms, hypsarrhythmia and variable mental retardation [30]. In 2003, two cases of 
unrelated female patients sharing a similar epileptic phenotype and hypsarrhythmia were 
reported by Kalscheuer et al. These patients presented an apparently balanced 
translocation where the X-chromosomal breakpoints disrupted CDKL5 [31].  
Since then mutations in CDKL5 have generally been associated with early infantile 
epileptic encephalopathy, ISSX, early onset seizures variant of RTT, West syndrome, 
Angelman or Angelman-like syndrome [32] [33]. 
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2.2.1 Clinical features of CDKL5-related pathologies 
 
The central clinical feature of CDKL5-related pathologies is epileptic encephalopathy, 
often characterized by intractable seizures starting within the fifth month of life. Epilepsy 
is in general polymorphic and various types of seizures could affect the same patient in 
different period of its life. 
In 2008, Bahi-Buisson et al. described three stages of CDKL5-related epileptic 
encephalopathy, consisting in early epilepsy (stage 1), infantile spasms (stage 2) and 
multifocal and refractory epilepsy (stage 3) [34].  
Early epilepsy (stage 1) is characterized by tonic-clonic seizures, lasting less then 1 
minute but very frequent and occurring usually 2-5 times per day. Stage 2 consists of 
infantile spasms and atypical hypsarrhytmia. It affects about 75% of CDKL5 patients, 
showing profound mental retardation, massive hypotonia and no language or visual 
interactions; such patients could face a honey-moon period (decrease or absence of 
seizures) when treated with anti-epileptic drugs during the progression into this stage. At 
last, stage 3 is shared by almost 71% of CDKL5 patients and presents multifocal and drug-
resistant seizures, including tonic spasms and myoclonia [34].  
Despite these evidence, to date no EEG data or MRI analysis identified an exact pattern 
or specific abnormalities in CDKL5 patients [31] [35] [36] [37]. 
Moreover, almost 55% of patients carrying genomic deletions or point mutations in 
CDKL5 acquire progressive microcephaly, while the few described patients with CDKL5 
duplications appear to exhibit macrocephaly [38]. Interestingly, in contrast with CDKL5 
deficiency, none of these patients showed epilepsy while learning impairment, autistic 
and hyperactive behaviours have been reported [38]. 
CDKL5 patients share some clinical features with RTT syndrome including hand 
stereotypes, severe hypotonia and altered psychomotor development but they do not 
exhibit the regression period that is considered one of the main criteria for RTT diagnosis 
[7]. In addition, different studies described cortical visual loss [37] [39] [40] [41], while 
intense eye gaze or neurovegetative functions including breathing abnormalities, cold 
extremities, gastrointestinal disturbances typical of classic RTT patients are not, or only 
occasionally, observed in CDKL5 patients [37] [42]. Moreover, about 30% of patients 
could be able to walk [37]. 
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Finally, contrarily to classic RTT, CDKL5 syndrome cannot be considered gender-
related. Indeed MECP2 mutations have been rarely found in males and generally give rise 
to a more severe encephalopathy leading to death within the first years of life [42]. On 
the contrary, Liang et al., analysing a cohort of patients affected by epileptic 
encephalopathy, observed a CDKL5 mutations frequency of 5% in males and 14% in 
females [35]. Furthermore, clinical severity seems to be similar in CDKL5 patients of 
both genders [35] [43] [44] even if Fehr et al. have observed in males a more severe 
phenotype characterized by slightly earlier seizures, inability to walk, impairments in 
spoken communication and hand functions [32]. Sartori et al. described a male affected 
by Klinefelter syndrome (47, XXY) and a large C-terminal CDKL5 truncation showing 
a similar phenotype to other CDKL5-mutated boys; such observation suggests that the 
presence of a wild-type CDKL5 allele and a balanced X inactivation pattern does not 
reduce the severity of disease [45] [42]. 
Altogether these studies highlight that, although mutations in CDKL5 have been 
originally associated with the early-onset variant of RTT, the gene is actually cause of a 
large spectrum of neurodevelopmental disorders that can be considered clinically 
separated from RTT. 
 
2.2.2 CDKL5 structure: from gene to protein 
 
The CDKL5 gene was identified analysing the Xp22 region through a positional cloning 
study aimed at isolating disease genes in this portion. Sequence analysis showed 
homologies to a subgroup of kinases, the serine-threonine kinases, and for this reason 
CDKL5 was firstly named STK9 (Serine-Threonine Kinase 9) [46]. Then, observing its 
similarity to some kinases involved in cell division [31], the protein was renamed as 
CDKL5/STK9 and finally CDKL5 (Cyclin-Dependent Kinase-Like 5). 
The mammalian CDKL5 gene structure and the related transcripts were studied in 
different species: human, mouse, rat.  
The human CDKL5 gene is composed of twenty-seven exons and can be alternatively 
spliced in five major transcript isoforms, which are named hCDKL5_1 to hCDKL5_5 
(Fig. 2) [47].  
hCDKL5_1 isoform is highly expressed in CNS, but can be detected in kidney, testis, 
prostate glands, thymus and thyroid gland; this transcript encodes the protein weighting 
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107 kDa that is the most abundant isoform in CNS. The hCDKL5_2 sequence is similar 
to the first one isoform but includes 123 bases (41 a.a.) from exon 17 lacking in 
hCDKL5_1. hCDKL5_3 and hCDKL5_4 share the same sequence of hCDKL5_1 and 
hCDKL5_2, respectively, but the utilisation of a cryptic splice donor site gives rise to a 
coding sequence lacking 51 bases at 3’ end of exon 11 codifying therefore for a shorter 
protein. hCDKL5_2, hCDKL5_3 and hCDKL5_4 are widely expressed but with lower 
abundance than hCDKL5_1. The last isoform, hCDKL5_5, is similar to hCDKL5_1 and 
hCDKL5_3 but is characterized by a different 3’ sequence due to the use of a cryptic 
splice site in exon 19 and the inclusion of exons 20, 21, 22; in addition such isoform was 
found to be less stable if compared to hCDKL5_1 [48]. In adult, hCDKL5_5 transcript is 
only expressed in testis and codify for a protein weighting 115 kDa [47].  
The murine Cdkl5 gene comprises a total of twenty-three exons giving rise to five major 
transcript isoforms [47]. The first two isoforms are orthologous to hCDKL5_1 and 
hCDKL5_2 and have thus been named mCdkl5_1 and mCdkl5_2. Contrarily, the 
remaining isoforms do not have full orthology and are thus named mCdkl5_6, mCdkl5_7 
and mCdkl5_8. 
 
 
Figure 2. Graphical representation of CDKL5/Cdkl5 gene structures. 
A) Schematic illustration of the human CDKL5 gene and its five different splicing isoforms (hCDKL5_1 
to hCDKL5_5). Splicing events are indicated as angled lines linking exons while dotted lines within 
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exons show alternative splice sites. Asterisks indicate where differences between isoforms have been 
found  [47].  
B) Schematic correlation between human, mouse and rat CDKL5 gene structures [49]. 
 
Concordantly with its human orthologous, mCDKL5_1 is the most abundant isoform in 
CNS, while the expression of mCdkl5_6 and mCdkl5_7 is confined to adult murine testis; 
mCdkl5_8 is transcribed in spleen and, at lower levels, in brain, heart, liver, lung and 
testis [47].  
Recently, the rat Cdkl5 was also characterised by Hector et al.; the gene is organized in 
twenty-three discrete exons codifying for four distinct transcript isoforms: rCdkl5_1, 
rCdkl5_2, rCdkl5_9 and rCdkl5_10 [49]. The first two isoforms are the most abundant in 
rat brain and share a similar expression pattern of their orthologous h/mCDKL5_1 and 
h/mCDKL5_2. rCdkl5_9 and rCdkl5_10 are predominantly expressed in testis. 
The analysis of the 5’ and 3’ ends of CDKL5 transcripts has identified multiple 
Transcription Start Sites (TSS) and polyadenylation signals. In particular, in the first two 
isoforms the major 5’ TSS and canonical 3’ polyadenylation signal are maintained 
between the three species [47] [49]. 
 
Cdkl5-mRNA is highly expressed in brain and mainly in adult forebrain reaching a peak 
in more superficial cortical layers. In particular, a strong expression was detected in 
specific cortical area, including frontal cortex, motor cortex and cingulate gyrus, 
suggesting a region specific role for CDKL5 [42]. Importantly, high levels of Cdkl5-
mRNA have been also detected in hippocampus and entorhinal cortex, two areas 
important for memory and learning, and in several thalamic nuclei. In cerebellum, Cdkl5-
mRNA is expressed in all lobules but its level seems to be lower if compared to the other 
brain areas [42]. 
Considering the different neuronal sub-populations, Cdkl5-mRNA appears 
predominately expressed in  glutamatergic and GABAergic neurons, while at very low 
levels in dopaminergic areas (substantia nigra or ventral tegmental area) or in 
noradrenergic areas (locus coeruleus) [42]. Interestingly, Cdkl5-mRNA is localised in the 
entire neuronal cell body, from soma to dendritic spines where the protein is locally 
synthetized after stimuli [50].  
The protein expression mainly coincides with the described mRNA expression levels 
[51]. Considering the different neural populations, the kinase is highly expressed in 
virtually all NeuN-positive neurons while very low expression is detectable in glia [51]. 
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Moreover, CDKL5 expression is modulated during development and it is characterized 
by low expression during embryogenesis, with a strong increase during postnatal period 
reaching a plateau at P14 [52]. 
 
CDKL5 is a serine-threonine kinase belonging to CMGC family which includes the 
cyclin-dependent kinases (CDK), the mitogen-activated protein kinases (MAP kinases or 
ERKs, extracellular-signal-regulated kinases), the glycogen synthase kinases (GSK) and 
the CDK-like kinases. It is characterized by an N-terminal catalytic domain sharing 
homology with the other members of CDKL-family and a long C-terminal tail unique for 
CDKL5.  
 
 
 
Figure 3.  Schematic illustration of CDKL5107 structure. 
Representation of different functional domains and signatures distributed along the protein. In blue is 
represented the N-terminal catalytic domain containing the ATP-binding site, the serine/threonine active 
site and the TEY motif. In white is shown the C-terminal tail carrying two nuclear localisation signals 
(NLS1 and NLS2) and three PxxP sites (arrowheads). Adapted from Kilstrup-Nielsen et al., 2012 [42]. 
 
In the catalytic domain (a.a. 13-297, Fig. 3) specific signatures of serine-threonine kinase 
group have been identified, which includes (i) an ATP-binding motif (a.a. 19-43) 
composed by a glycine-rich stretch close to a lysine residue (K42) involved in ATP 
binding [53]; (ii) a serine-threonine active site (a.a. 131-143) including a conserved 
aspartic acid (D135) crucial for catalytic activity [53]; (iii) an “activation loop” with a 
DFG domain and a TEY motif (DFGFARNLSEGNNANYTEY; a.a. 153-171). As for 
other members of the CMGC family, during activation, the TEY motif (a.a. 169-171) is 
dually phosphorylated through an auto- or hetero-phosphorylation process, while the 
conserved DFG motif stabilizes the active conformation forming polar contacts with other 
regions of the kinase [54] [55] [42]. 
On the other hand, the C-terminal tail, that is not homologous to regions of other human 
proteins, appears to function as a regulatory portion of the protein. In fact, it has been 
proved to negatively regulate the catalytic activity of the kinase and to modulate its 
stability [55]. Moreover, the C-terminal tail of CDKL5 regulates its capability to shuttle 
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between nucleus and cytoplasm [52]; in this region are indeed present two putative 
nuclear localisation signals (NLS1, a.a. 312-315, NLS2 a.a. 784-789) and a putative 
nuclear export signal (NES, a.a. 836-845). Finally, in the C-terminal portion of CDKL5 
can be identified three PxxP sites constituting putative binding site for Src homology 3-
domain proteins, including Proto-oncogene tyrosine-protein kinase Src and Growth factor 
receptor-bound protein 2 (Grb2) [55].  
 
2.2.3 CDKL5 mutations 
 
The analysis of a database collecting genetic alterations (http://mecp2.chw.edu.au) in 
CDKL5 permitted to identify  498 variants of which 178 are pathogenic mutations and 
can be divided into missense, nonsense, frameshift, splice-site mutations and more 
complex rearrangements [56].  
 
 
 
Figure 4.  Graphical representation of CDKL5 mutations. 
Illustration of CDKL5 mutations according to Kilstrup et al., 2012 [42] and Hector et al., 2016 [47]. 
Mutations above the gene are indicated using cDNA nomenclature and they consist in splice variants, 
deletions and frameshift mutations as described in Kilstrup et al., 2012 [42]. Below the gene missense 
(black) and nonsense (red) mutations were integrated with RettBASE database (http://mecp2.chw.edu.au) 
and they are represented with amino acid nomenclature. *: uncertain pathogenicity; bold text: benign or 
likely benign variants. 
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Pathogenic missense mutations are almost exclusively localised in the kinase domain 
suggesting the crucial role of this region for maintaining CDKL5 proper function (Fig. 
4). Indeed, C152F and R175S, mutations that falls in the catalytic domain, have been 
correlated to altered phosphotransfer activity and impaired kinase activation or substrate 
specificity, respectively [54]. 
 
On the contrary, nonsense mutations are equally distributed along the entire open reading 
frame (Fig. 4 in red). In particular, nonsense mutations located in the last portion of the 
C-terminal tail cause a mis-localisation of the kinase leading to its accumulation in the 
nucleus [52]. Although we are still lacking extensive genotype-phenotype studies, some 
evidence suggested that alterations in the C-terminal tail give rise to milder phenotypes 
[42].  
Duplications of CDKL5 were also reported indicating that a tight regulation of the kinase 
expression level is crucial for the CNS [38]. 
 
2.2.4 CDKL5 functions 
 
Functions of a protein are strictly correlated with its localisation and its specific, and often 
regulated, protein-protein interactions.  
In both proliferating cells and neurons, CDKL5 can be identified into the nucleus and 
cytoplasm [54] [52] [57] (Table 2). In nuclear compartment of hippocampal neurons and 
in mouse brain, the kinase shows a diffuse staining with brilliant dots not overlapping 
with the heterochromatic DAPI-positive DNA, while finely dotted CDKL5-positive 
puncta can be identified in soma, neurites and in dendritic spines [57] [58].  
Subcellular localisation of CDKL5 is influenced by several factors including the cellular 
maturation stage and activity, and the protein phosphorylation state. 
Indeed, in neurons CDKL5 is mainly cytoplasmic during embryogenesis while the 
nuclear fraction increases in postnatal stages until adulthood [52]. Moreover, the 
phosphorylation by dual specificity tyrosine-phosphorylation-regulated kinase 1a 
(DYRK1A) leads to an increase of cytoplasmic CDKL5 when the two kinases are co-
expressed in mouse neuroblastoma Neuro2a cells  [59].  
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Stimulation is one more factor that influence CDKL5 localisation. In particular, glutamate 
stimulation determines to a rapid exit of CDKL5 from the nucleus followed by massive 
proteasome-dependent degradation in hippocampal neurons [57].  
Furthermore, localised synthesis of CDKL5 in dendrites and in dendritic spines is 
activated by neuronal activity; this induction occurs at all stages of neuronal maturation 
but it is prolonged in young neurons, while in mature neurons the activation of NMDA 
receptor induces a protein phosphatase 1-dependent dephosphorylation and a subsequent 
proteasome-dependent degradation of CDKL5 [50].  
 
2.2.4.1 Nuclear functions of CDKL5: regulation of gene expression 
 
In the nucleus CDKL5 was found to associate with different proteins including MeCP2, 
DNA (cytosine-5)-methyltransferare 1 (DMNT1) and SR-family splicing factor 35 
(SC35) (Table 2); such interactions suggest a role in the regulation of gene expression. 
In vitro biochemical data indicate that CDKL5 can associate with and phosphorylate 
MeCP2 supporting the hypothesis that such proteins belong to the same pathway; these 
data might be sustained by the partial overlapping clinical phenotype  [60] [54]. Of note 
the C-terminal domain (precisely a.a. 450-550) seems to be required for the interaction 
with the methyl-binding protein [60].  
Moreover, Kameshita et al. have demonstrated the capability of CDKL5 to bind and 
phosphorylate the N-terminal region of DNMT1 in vitro using a truncated derivative of 
CDKL5 containing only the catalytic domain. Nevertheless, additional studies are 
required to confirm this capability in vivo and in the presence of a full-length CDKL5 
[61]. Finally, Ricciardi et al. have shown that CDKL5 co-localises with and co-
immunoprecitates SC35 in nuclear speckles in vivo and in vitro. In addition, the authors 
have demonstrated that CDKL5 mis-expression is able to alter nuclear speckles and this 
is mostly dependent on the catalytic activity. Interestingly, using minigene-based splicing 
assays, it has been verified that loss of CDKL5 causes splicing defects [62]. 
 
2.2.4.2 Cytoplasmic functions of CDKL5: regulation of neuronal morphogenesis and 
dendritic spines development 
 
In cytoplasmic compartment, CDKL5 has crucial roles in the regulation of neuronal 
morphogenesis and excitatory spine development.   
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Deregulated expression of CDKL5 severely alters different aspects of neuronal 
morphology including dendritic arborisation, polarisation and dendritic spine shape. 
Indeed, CDKL5 silencing in cortical neurons resulted in a reduction of dendrites and 
axons total length together with a delayed neuronal migration [51]. Likewise, CDKL5 
knockdown gave rise to a polarisation defect exhibited by the presence of several neurons 
displaying no axon or the presence of multiple axons; this defect is at least in part 
mediated by the association of CDKL5 with shootin1, a key brain protein in axonal 
formation and neuronal polarisation [63]. Moreover, CDKL5 silencing has determined an 
increase in dendritic protrusion density and the generation of thinner and filopodia-like 
spines together with a reduction of number of excitatory synapses and synaptophysin 
puncta. Such defects in spine structure are correlated to impaired synaptic activity: 
CDKL5 knockdown neurons have shown reduction in mEPSCs [58].  
The morphological abnormalities observed in vitro in silenced neurons have been 
confirmed also in vivo using Cdkl5 mouse models [64] [65] [66]. 
The capability to modulate neuronal morphology is also highlighted by CDKL5 
interaction with proteins involved in the regulation of microtubule  [67] or actin 
cytoskeleton (Table 2) [51] [58]. 
Barbiero et al. have described a novel role of CDKL5 in the regulation of microtubule 
dynamics through the interaction with IQGAP1 (IQ domain-containing GTPase-
activating protein 1), an important modulator of cell migration and polarity [67]. In this 
work, the authors have evidenced that the absence of CDKL5 leads to an altered cell 
migration together with the displacement of IQGAP1 from cellular leading edge and the 
reduction of its capability to interact with Rac1 and CLIP170 (+TIP cytoplasmic linker 
protein 170). Interestingly, the altered capability of CLIP170 to bind microtubules and 
morphological neuronal defects due to CDKL5 silencing was rescued using the 
neurosteroid pregnenolone, a ligand of CLIP170 receptor [67]. 
CDKL5 involvement in the regulation of actin cytoskeleton was also suggested by its 
association with an important regulator of actin cytoskeleton, Rac1 (Ras-related C3 
botulinum toxin substrate 1), and by its co-localisation with F-actin in the peripheral 
domain of growth cones in neurons (Table 2) [51]. Interestingly, BDNF stimulation 
enhances the CDKL5-Rac1 interaction and leads to a transient increase of CDKL5 
phosphorylation suggesting a role of CDKL5 in BDNF-induced activation of Rac1 [51].  
The regulation of spine development and synaptic activity is also mediated by the 
association of CDKL5 with NGL-1, a lipid anchored protein structurally related to netrin 
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family of axon guidance molecules [68]. CDKL5 binding leads to NGL1 phosphorylation 
strengthening its interaction with PSD95, a transmembrane protein localised in the Post 
Synaptic Density (PSD). Beyond NGL-1, CDKL5 interacts in PSD with the other two 
members of the NGL-family (NGL-2, NGL-3) and co-localises in vivo and in vitro with 
excitatory synaptic markers including PSD95, Shank (SH3 and multiple ankyrin repeat 
domains), NR2 (NMDA Receptor subunit 2) and VGLUT1 (Vescicular Glutamate 
Transporter 1; Table 2) [58].  
Two more cytoplasmic CDKL5 substrate are amphiphysin 1 (Amph1) and Histone 
Deacetylase 4 (HDAC4, Table 2). The first one is a protein involved in synaptic vesicles 
recycling through clathrin-mediated endocytosis whose phosphorylation by CDKL5 
negatively influences its binding to endophilin, an important factor in synaptic vesicle 
endocytosis [69]. The second one is a class II histone deacetylase expressed at high level 
in neurons and normally retained in cytoplasm in a phosphorylated state; the loss of 
CDKL5 determines a decrease of HDAC4 phosphorylation leading to its the nuclear 
translocation [70]. 
 
 
 
Table 2. Representation of CDKL5 interactors identified to date.  
For each protein is indicated the subcellular compartment where the interaction occurs and, if available, the 
region of CDKL5 involved in the association. nd: not determined. DYRK1A [59]; MeCP2 [60]; DNMT1 
[61]; SC35 [62]; Shootin1 [63]; IQGAP1 [67], Rac1, F-actin [51]; NGL-1/2/3, PSD95, Shank, NR2, 
VGLUT1 [58]; Amph1 [69]; HDAC4 [70]. 
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To conclude Livide et al., have recently identified a deregulation of GRID1 (encoding for 
glutamate D1 receptor 1, GluD1) in CDKL5 patients’ derived cells [71]. GluD1 functions 
as an adhesion molecule binding presynaptic neurexin through cerebellin and inducing 
presynaptic differentiation. The authors have found that GRID1 expression is 
downregulated in iPS (induced Pluripotent Stem) cells, while it is upregulated in NPCs 
(Neural Precursors Cells) and in mature neurons. Interestingly, the same GRID1 
expression profile was found in MECP2 patients’ derived cells, while chromatin 
immunoprecipitation (ChIP) analysis in SHSY-5Y cells indicated the capability of 
MeCP2 to bind the GRID1 promoter. These data support the already mentioned possible 
molecular link between MeCP2 and CDKL5 [71].  
 
2.2.4.3 Mouse models: recapitulating pathophysiology of CDKL5-related pathologies 
 
To better understand the different functions and roles of CDKL5 and to improve the 
knowledge of the pathophysiology of CDKL5-related diseases, three different mouse 
models have been generated. 
 
The first Cdkl5 knockout mouse model was described by Wang et al. in 2012 (C57BL/6 
background); it was generated by deleting exon 6 via homologous recombination in 
Embryonic Stem (ES) cells, therefore causing a premature truncation in the N-terminal 
catalytic domain [64]. 
Cdkl5-/Y mice exhibit subtle but consistent hyperactivity, motor defects, including 
hindlimb and forelimb clasping, and reduced anxiety; these phenotypes have already been 
described in mouse models of RTT and autism spectrum disorder (ASD) [1] [72]. 
Additional behavioural tests evidenced deficits in social interactions, learning and 
memory.  
Although seizures are a hallmark of CDKL5-diseases, EEG recordings in the generated 
Cdkl5-null mouse evidenced a normal EEG pattern with the absence of spontaneous 
seizures, therefore posing some concerns on the face validity of this animal model that is 
generally characterized by very mild symptoms. However, the analysis of event-related 
potential (ERP), as a measure of cognitive processes, showed delayed ERP polarity 
suggesting impaired neuronal connectivity.  
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Amendola et al. described a second conditional mouse model generated through the 
deletion of Cdkl5 exon 4 (C57BL/6 background) [65]. Concordantly with Wang’s mouse 
model, knockout mice do not show spontaneous epileptic activity and abnormal EEG can 
be recorded only after convulsant treatment. Moreover, monitoring the responses to a 
moving visual stimulus in visual drum test, the authors have verified a reduction in the 
number of head tracks in knockout compared to wild type mice together with a decrease 
of visual evoked responses (VEPs). 
Different behavioural analyses of this line of Cdkl5-/Y mice revealed locomotor 
impairments including hindlimb clasping and, in contrast to Wang et al. mouse model, 
hypoactivity [65] together with deficits in hippocampus-dependent learning and memory 
[73] [70]. Moreover, selective Cdkl5 knockout in different forebrain population has 
allowed to correlate the diverse motor behavioural phenotypes with specific neuronal 
subpopulations: deficits in limb clasping and head tracking was associated with 
glutamatergic neurons while hypolocomotion with GABAergic neurons.  
The localisation of Cdkl5 at synapses and the reported synaptic alteration after Cdkl5 
knock-down pushed up several synaptic studies in Cdkl5 knockout mice. 
Synaptic analyses of knockout mice have been performed in several brain regions 
including hippocampus [73] [70], somatosensory cortex [74], primary visual cortex (V1) 
[75] and cerebellum [76] and evidenced region-specific phenotypes. 
Hippocampal Cdkl5-/Y neurons showed reduced dendritic arborisation with immature 
dendritic spines and, in CA1 pyramidal neurons,  reduced spine density [73] [70] 
confirming previous evidence obtained in vitro and highlighting the role of CDKL5 
during neuronal development [51] [58]. Moreover, a reduction in synaptophysin and 
VGLUT1 presynaptic markers in hippocampal dentate gyrus neurons suggested an 
impairment in synaptic contact maintenance [73]. 
Indeed, using two photon imaging, Della Sala et al. identified an impairment in dendritic 
spine maintenance as the cause of reduced spine number in Cdkl5-/Y somatosensory cortex 
[74]. While, in fact, new spines were normally generated, they were more effectively 
eliminated in the absence of Cdkl5. This resulted in a strong decrease in pyramidal spine 
density associated with a reduction of PSD95 expression. Morphological defects reflected 
impaired synaptic transmission and plasticity in terms of miniature EPSCs and LTP 
(Long-Term Potentiation).  
Synaptic connectivity impairments in V1 of Cdkl5-/Y mice were described in a recent study 
[75]. The author evidenced a profound cellular and synaptic disorganisation in V1 
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characterised by a higher density of parvalbumin positive interneurons which are 
hyperconnected with pyramidal neurons together with a severe reduction of postsynaptic 
PSD95 and Homer and an upregulation of VGLUT1. Such alterations may cause a shift 
in the excitation/inhibition balance and were, indeed, associated with a severe 
downregulation of c-Fos expression indicating a general circuit hypoactivity in V1 [75]. 
A recent study evidenced Cdkl5-dependent deficits also in the cerebellum [76]. The 
cerebellum analysis has shown a high reduction of GABA-efflux and, in molecular layer, 
a selective defect of glutamic acid decarboxylase 67 (GAD67), a specific marker of 
GABAergic interneurons, suggesting inhibitory deficits. Moreover, Rotarod and Catwalk 
behavioural tests evidenced impaired motor functions in Cdkl5 knockout mice [76]. 
 
The third mouse model was recently described by Okuda et al. deleting Cdkl5 exon 2 in 
C57BL/6 genetic background mice [66]. In accordance with previously described Cdkl5 
mice, Okuda Cdkl5-/Y mice did not show spontaneous seizures. However, NMDA 
administration induced severe generalised tonic-clonic seizures in Cdkl5-/Y mice, 
indicating an abnormal NMDAR-mediated response. Electrophysiological analyses in 
hippocampal CA1 region revealed enhanced synaptic plasticity mediated by GluN2B-
containig NMDARs. Indeed, hippocampal subcellular fractionation revealed an 
accumulation of GluN2B-containig NMDARs and SAP102 at the postsynaptic site of 
Cdkl5-/Y excitatory synapses. This accumulation seems to account for the enhanced 
seizure susceptibility in knockout mice. Interestingly, the administration of ifenprodil, a 
GluN2B selective antagonist, abrogated the NMDA-induced hyperexcitability [66]. 
 
2.2.4.4 Molecular alterations associated to CDKL5 depletion 
 
Considering the serine/threonine kinase activity of CDKL5, the identification of its 
substrates is crucial for understanding the consequences of CDKL5 loss.  
For these reasons, Wang et al. performed a Serine/Threonine (S/T) kinome profiling of 
different brain areas: striatum, cortex, hippocampus and brainstem. From such analysis 
emerged alterations in many signal transduction pathways in Cdkl5 knockout mice and, 
in particular, in AKT/mTOR signaling cascade, an important pathway regulating protein 
synthesis. In accordance, a reduction of rpS6 phosphorylation, a ribosomal protein 
important for protein translation and whose activation depends on AKT, was detected 
[64]. The downregulation of AKT and rpS6 phosphorylation was confirmed in successive 
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studies [65] [74] and, interestingly, the administration of Insuline-like Growth Factor 1 
(IGF-1), an activator of AKT/mTOR/rpS6 pathway already tested in RTT mice, was able 
to rescue altered rpS6 phosphorylation, spine deficits and PSD95 expression level [74]. 
In recent studies, Fuchs et al. identified a deregulation of the AKT/GSK-3b signalling 
pathway in the absence of Cdkl5 [77] [73]. In particular, Cdkl5-/Y showed hyperactivation 
of Glycogen Synthase kinase 3 beta (GSK-3b), a crucial regulator of many 
neurodevelopmental processes, and generated new-born granule cells with reduced length 
and number of branches [77]. Considering the elevated activity of GSK-3b, the use of a 
GSK-3b inhibitor (SB216763) was sufficient to restore both defective dendritic and spine 
morphology in Cdkl5-/Y granule cells and hippocampal pyramidal neurons and to improve 
impaired learning capabilities of Cdkl5-/Y mice [73]. 
A novel direct phosphorylation target of CDKL5 was recently identified by Trazzi et al. 
[70]. This study reports a downregulation of Histone Deacetylase 4 (HDAC4) 
phosphorylation in Cdkl5-null cells therefore leading to its accumulation into the nucleus 
and, consequently, to the reduction of H3 acetylation. This hypophosphorylation state 
makes the protein more active in the nucleus; interestingly, a specific inhibitor for 
HDAC4/HDAC5 (LMK235) was able to normalise survival and maturation of neuronal 
precursor cells, dendritic morphology and hippocampus-dependent memory that were 
impaired in Cdkl5-/Y mice [70]. 
 
2.2.4.5 CDKL5 roles in proliferating cells 
 
Given the ubiquitous expression of CDKL5 and its belonging to the same family of MAP 
and cyclin-dependent kinases, its possible roles in proliferating cells have also been 
investigated. 
A study in SH-SY5Y neuroblastoma cell line indicated that CDKL5 can inhibit cell 
proliferation causing an arrest in G0/G1 phases [78]. 
Furthermore, we have demonstrated that CDKL5 is important for faithful cell division 
[79]. Indeed, in proliferating cells, endogenous CDKL5 shows a dynamic localisation 
during cell cycle: in prophase and in metaphase it is detectable at mitotic spindle poles, 
while it localises at the midbody during cytokinesis. Importantly, the localisation at the 
centrosome was also detected in cultured neural progenitors and in post-mitotic primary 
hippocampal neurons [79].  
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The role of CDKL5 during cell cycle was more deeply dissected. In particular, CDKL5 
knockdown determines a significant increase in the number of cells with multipolar 
spindles together with several defects in chromosomal segregation including 
anaphase/telophase chromosome bridges, micronucleation and binucleated cells. 
Moreover, the high number of cells positive for phosphorylated histone H3-S10, a mitotic 
marker, indicates that these cells accumulate in mitosis [79]. Rescue experiments 
expressing a siRNA resistant CDKL5 confirmed that these alterations depend on CDKL5. 
In addition, microscope analyses of siCDKL5 HeLa cells have evidenced that spindle 
multipolarity is due to supernumerary centrosomes arising from centrosome 
accumulation as a consequence of cytokinesis failure [79].  
At the molecular level, interfered midbodies have shown decreased levels of HIPK2 
(Homeodomain-Interacting Protein Kinase 2) and its cytokinesis target H2B 
(extrachromosomal histone H2B) phosphorylated at S14 [79]. Importantly, spindle 
multipolarity of CDKL5 knocked down cells was overcome using a phosphomimetic 
H2B-S14D derivative capable of rescuing cytokinesis failure in HIPK2-defective cells 
[80]. In this work, we have thus demonstrated a novel role of CDKL5 in the regulation of 
cell division through HIPK2-mediated H2B phosphorylation [79]. Since this topic has 
been one of the two main focuses of the first year of my PhD studies I have included the 
paper at the end of this dissertation. 
Of interest and as already mentioned, Bergo et al. have recently identified an interaction 
of MeCP2 with centrosome; however, the two proteins seem to have different functions 
in this organelle [16]. 
Additional evidence of CDKL5 involvement in cell proliferation was provided by Fuchs 
et al. in the context of adult neurogenesis [77]. In this study, a quantitative analysis of 
BrdU (Bromodeoxyuridine)-positive or Ki67-positive progenitor cells in P45 
hippocampal dentate gyrus (DG) led the authors to suggest an increase of proliferation in 
both Cdkl5-/- and Cdkl5Y/- mice compared to wild-type.  However, in possible good 
accordance with our results, the count of BrdU-positive cells in P75 DG showed no 
difference between Cdkl5-/-, Cdkl5Y/- and wild-type mice indicating that the higher 
proliferation degree at P45 is associated with a reduction of the survival rate. 
Accordingly, the expression of cleaved caspase-3 highlighted an increase of apoptotic 
cell death in newborn postmitotic neurons. Interestingly, the number of astrocytes is not 
altered suggesting that loss of Cdkl5 does not affect astrogliogenesis [77]. 
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2.3 Therapeutic approaches for CDKL5-related pathologies 
 
The identification of logically designed therapeutic approaches requires a profound 
comprehension of disease pathophysiology.  
To date CDKL5 functions and the consequences of its loss are poorly understood 
therefore postponing the development of logically designed therapies.  
Promising alternatives to drug-based therapies are gene- and protein-augmentative 
therapies. However, in both cases, the subtle regulation of Cdkl5 mRNA and protein 
(including subcellular localisation and local translation), the high turnover of the kinase 
and the dosage issues together with the capability to target in females only cells 
expressing the mutant X-linked allele, make these approaches unfeasible to date.  
However molecular genetics suggests the possibility to test different strategies depending 
on the specific mutation, therefore, functioning as “personalised medicine”. Among these 
we found worth for testing the therapeutic potentiality of PTC (Premature Stop Codon) 
suppression. 
 
2.3.1 Read-through approach 
 
Translation termination occurs when a stop codon (UAA, UAG or UGA) enters into the 
ribosomal A site inducing the release of the polypeptide chain from the peptidyl-tRNA 
[81]. 
In the presence of a PTC originating from a nonsense mutation, different mechanisms can 
be activated including translation termination releasing truncated polypeptides, Nonsense 
Mediated Decay (NMD) and PTC suppression. NMD is a quality control pathway 
determining the degradation of PTC-containing mRNA and then avoiding the generation 
of potentially dominant negative truncated proteins [81]. PTC suppression requires a 
near-cognate aminoacyl-tRNA that by binding two of the three bases of a PTC bypasses 
the premature stop codon [82] [81].  This process, also known as read-through, allows 
protein elongation until the natural stop codon, therefore generating a full-length 
polypeptide (Fig. 5). 
The suppression of an in-frame PTC determines the incorporation of one of several 
possible amino acids: seven different amino acids could be incorporated at UAG site, 
while six at UGA or UAA codons (Table 3) [82]. In each case, if PTC arose from a single 
nucleotide change, one of these amino acids leads to the synthesis of a WT protein. 
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Different studies have demonstrated that the residue inserted after read-through depends 
on the PTC. In vitro data have identified tryptophan, cysteine and arginine as the preferred 
inserted amino acids in case of an UGA stop codon, while glutamine is more likely to be 
found in presence of UAA and UAG stop sites [83] [84] [85] [86]. By establishing a 
reporter system in yeast, Blanchet et al.  have recently defined the incorporation rate at 
different PTCs: 54% for tyrosine, 44% for glutamine, and 2% for lysine at UAA stop 
codon; 92% tyrosine, 5% glutamine, and 3% lysine at UAG stop codon; 82% tryptophan, 
14-17% cysteine, 1-4% arginine at UGA stop codon [87].  
As mentioned, the read-through is just one of the possible outcomes in the presence of a 
PTC; its frequency is affected by several factors, including tRNA abundance, release 
factors levels, PTC type and the surrounding mRNA sequence. In particular, the highest 
read-through efficiency was found at UGA stop codon, while UAA appeared as the least 
efficient [88] [89] [90] [91].  
 
 
 
Figure 5.  Schematic representation of the main mechanisms occurring when a ribosome encounters 
a PTC.  
The presence of a PTC at the ribosomal A-site can determine translation termination or read-through. In 
the first case, the binding of eRF1 and eRF3 release factors determines the release of the truncated 
polypeptide followed by disassociation of ribosomal subunits. Rarely the production of a full-length 
polypeptide can occur thanks to the association of a near-cognate tRNA [81]. 
 
PTC nucleotide context is one of the main factors influencing read-through efficiency. In 
particular, the CUAG sequence immediately downstream the stop codon or more 
generally the sequence CARYYA (R for purine and Y for pyrimidine) appeared to 
facilitate read-through [88]. Moreover, the highest rate of gentamicin-induced read-
through was found in the presence of a uridine at -1 and a cytosine at +4 positions respect 
to PTC [92]. However, the influence of nucleotide context may differ according to the 
PTC identity. Indeed, Manuvakhova et al. have demonstrated that in most cases the best 
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read-through rate occurs when the position +4 is occupied by a cytosine for UGA and 
UAA stop codons or by an uracil for UAG [91]. 
Data from diverse studies have evidenced that basal PTC suppression occurs with a rate 
between 0.001 to 0.1% at natural stop codons [93] that increases up to 1% at PTCs [94] 
[91]. However, different types of molecules can be used to induce PTC suppression 
including suppressor tRNAs or chemical compounds. The former have been generated by 
modifying the anticodon sequence of an exogenously expressed tRNA in order to allow 
the recognition of the premature stop codon [95]; however, since the recognition of 
natural stop codon cannot be excluded, to date their use appears not feasible for PTC 
suppression therapy [96]. 
 
 
Table 3. Possible amino acid substitutions during read-through at different PTC sites.  
Representation of amino acids deriving from the mispairing between a near-cognate aminoacyl tRNA and 
a stop codon. For simplicity, this table shows all possible codons deriving from a single mismatch at the 
three different positions rather than the corresponding tRNA anticodons [82]. 
 
On the other hand, the pharmaceutical approach exploits molecules that by binding to 
ribosomal subunits foster the association of a near-cognate tRNA with the PTC [82]. 
Considering that about 11% of human genetic diseases can be caused by in-frame 
nonsense mutations, several studies have tested read-through drugs in different 
pathological contexts including Duchenne muscular dystrophy (DMD) [97], cystic 
fibrosis (CF) [98] [99], ataxia-telangiectasia (ATM) [100], Usher syndrome [101], factor 
VII deficiency [102], retinitis pigmentosa [103] and Rett syndrome [89].  
Read-through drugs comprise a wide range of molecules including aminoglycosides, 
designer aminoglycosides and non-aminoglycosides. 
The first one comprises several compounds; among these, drugs carrying a hydroxyl at 
C6’ in the ring I (e.g. G418 or paromomycin) seem to more be more efficient in PTC 
suppression [104]. Studies in prokaryotic ribosomes have indicated that aminoglycosides 
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bind the helix 44 of 16S rRNA which is located at the base of ribosomal A site [82]. The 
binding of paromomycin in the decoding region has been found to induce a 
conformational rearrangement of the universally conserved nucleotides A1492 and 
A1493 in the ribosomal A site devoid of a tRNA [105]. The induced conformational 
change seems to alter the discrimination of near-cognate tRNA and to hinder the entry of 
release factors, thus stimulating read-though. Although rRNA structure is evolutionary 
well conserved, the modification of two bases changes in the 18S rRNA with respect to 
16S rRNA seems to reduce aminoglycoside binding to eukaryotic decoding site [82]. 
Aminoglycoside-derived read-through has been extensively tested in different 
pathological contexts including cell lines and mouse models harboring premature 
nonsense site in genes such as CFTR (Cystic fibrosis transmembrane conductance 
regulator) and DMD (Duchenne muscular dystrophy) [98] [99] [97]. Promising results 
have led to diverse clinical trials using gentamicin for the treatment of Cystic Fibrosis 
(CF) and Duchenne Muscular Dystrophy (DMD) patients. While initial clinical trials in 
DMD patients did not report clinical benefits [106], a subsequent study with an extended 
time of treatment has shown the expression of dystrophin in DMD patients together with 
a decrease in serum creatine kinase levels [107]. The clinical trial in CF patients has led 
to controversial data: two studies reported clinical benefits and enhanced CFTR-mediated 
chloride transport after gentamicin treatment [108] [109], while Clancy et al. did not 
reported any improvement in sweat chloride measurements [110].  
Although different aminoglycosides have shown good capability to induce read-through, 
their toxicity at therapeutic doses has limited their use in clinical practice. Long-term 
treatment leads to irreversible ototoxicity and reversible nephrotoxicity that are unrelated 
to read-through activity [111] [112] [113] [81]. Indeed, the intracellular uptake of 
aminoglycosides in renal proximal tubules and in hair cells of inner ear is associated with 
their binding to lysosomal acidic phospholipid and with the inhibition of mitochondrial 
protein synthesis determining the alteration of different enzyme functions and the 
generation of reactive oxygen species (ROS). 
Different strategies have been explored to decrease the toxicity of this therapeutic 
approach. 
In particular, the advantages of co-administrating together with gentamicin antioxidants 
[114] or poly-anions, such as poly-L-aspartate and daptomycin have been evaluated. 
Poly-anions were reported to alleviate nephrotoxicity and ototoxicity by binding 
aminoglycosides and preventing the association of the antibiotic with lysosomal 
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phospholipids [115] [116] [117] [82]. Interestingly, poly-L-aspartate administration leads 
to an increase of aminoglycoside cytoplasmic concentration and improved the read-
through efficiency in a CF mouse model [116]. 
By high-throughput screening in yeast, a new molecule, CDX5-1, was identified [118]. 
This compound was found to strongly increase the G418-induced read-through in vitro. 
Indeed, while CDX5-1 alone was not able to facilitate the read-through, in co-
administration with G418 it enhanced up to 180-fold the PTC suppression efficacy of 
TP53 R213X. Moreover, the combination of the two molecules improved also the read-
through in patients-derived cells carrying nonsense mutations in CLN2, SMARCAL1 and 
DMD genes [118]. 
 
A second approach involves the development of designer derivatives of existing 
aminoglycosides. Such drugs maintain the natural aminoglycoside backbone but present 
additional chemical groups that should decrease toxicity and/or enhance bioactivity [119].  
Designer aminoglycoside compounds include different groups of molecules: “TC” 
compounds derived by modification of neomycin, “JL” compounds by kanamycin B, 
“NB” compounds by paromomycin and geneticin [120]. Among “NB” compounds, the 
paromomycin derivative NB30 showed dose-dependent read-through activity but its 
efficacy was found to be lower than paromomycin or gentamicin. On the contrary, 
subsequent generations of “NB” compounds such as NB54 and NB84 have been reported 
to induce read-through more effectively than gentamicin [121]. In particular, NB84 
demonstrated a reduced ototoxic potential due by its decreased affinity for mitochondrial 
rRNA [122] and long-term NB84 treatment did not induced toxicity in an MPS I-H 
(mucopolysaccharidosis type I-Hurler) mouse model [123]. 
 
A third solution consists in identifying molecules that induce read-through but are 
unrelated to aminoglycosides. A group of non-aminoglycoside compounds was identified 
by high-throughput protein transcription/translation (PTT) ELISA-based assays. Such 
molecules, known as SMRT (Small Molecular Read-Through) compounds, include 
RTC13, RTC14 and GJ071, GJ072 [124] [125]. Read-through activity of RTC13 and 
RTC14 was reported in vitro testing different disease-genes, including ATM (ataxia 
telangiectasia) and dystrophin genes [124]. GJ071 and GJ072 compounds, identified in a 
second screen, have shown similar or even a better capability to induce read-through in 
ATM gene if compared to RTC13. In addition, most of the active analogs of GJ072 were 
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characterized by low partition coefficient (cLogP) indicating their ability to permeate 
tissues in case of an in vivo administration [125]. 
High throughput screening performed by PTC Therapeutics has led to the identification 
of another potentially promoting read-through compound, PTC124 (also known as 
Ataluren or Translarna™) [126].  
PTC124-induced read-through has been demonstrated by different in vitro and in vivo 
models of disease [127] [128] [129] [130] [131] [132] [133]. In addition, preclinical 
positive results together with reported low toxicity [134] have encouraged the initiation 
of different clinical trials in CF and DMD patient cohorts. PTC124 administration in CF 
patients has induced a substantial improvement in chloride conductance and a trend of 
improved pulmonary functions were observed [135] [136] [137] [135]; on the other hand, 
dystrophin protein production and reduction in serum creatine kinase were found in DMD 
patients [138] [139]. 
Nevertheless, the read-through activity of PTC124 is still under discussion. Indeed, 
several preclinical studies did not confirm the capability of PTC124 to suppress PTCs 
[140] [141] [142] [143], [144] [145] [146] [147] and their clinical efficacy was found to 
be weak in CF patients [148] [149]. Although the efficacy data lacked robustness, in 2014 
PTC124 received a conditional marketing authorization from the European Medicine 
Agency for DMD patients resulting from a nonsense mutation in dystrophin gene [150].  
 
Finally, beyond the toxicity associated with read-through drugs, the ability to cross the 
blood brain barrier (BBB) is an important issue for the treatment of CNS disorders. 
Aminoglycosides are mainly uptaken in mammalian cells through endocytosis mediated 
by megalin receptor [151]. Megalin is expressed in epithelial cells including brain 
ependymal cells which can delivery aminoglycosides in the cerebrospinal fluid [152]. 
Indeed, aminoglycosides such as gentamicin were reported to be able to cross the blood 
brain barrier to some extent [153] [154] [155]. Moreover, the administration of NB54 and 
NB84 has significantly reduced lysosomal glycosaminoglycan storage in the brain of 
nonsense mutation mouse models for MPS I-H disease [156] [123]. Such amelioration in 
the brain together with the low toxicity reported indicate the possibility to use these 
designer aminoglycosides in CNS diseases including CDKL5-related pathologies. 
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3. RESULTS 
 
3.1 Analysing the feasibility of PTC suppression in CDKL5-
related pathologies 
 
As already mentioned, some CDKL5 patients carry nonsense mutations and might benefit 
from a read-through strategy as “personalised medicine” approach.  
First screenings of read-through drug efficacy are generally performed transfecting cell 
lines with PTC-containing constructs and verifying the capability of treated cells to 
generate full-length products. Considering that CDKL5 pathogenic missense mutations 
are mainly localised in the N-terminal catalytic domain while nonsense mutations are 
uniformly distributed in the coding sequence, we have decided to study the read-through 
of PTCs localised in different CDKL5 regions.  
We selected mutants by analysing the database collecting human genetic alterations in 
CDKL5 patients (http://mecp2.chw.edu.au/cdkl5/index.php) and we chose nonsense 
mutations located either in the N-terminal catalytic domain (R59X, R134X, Fig. 6A) and 
in the C-terminal tail (Q347X, E364X, R550X, S855X, Fig. 6A). We hypothesized that 
C-terminal mutations could be more suitable for these studies because the amino acid 
substitution possibly introduced by PTC suppression might produce a protein that 
maintains most of its functions. Moreover, considering the importance of stop codon type 
in the read-through approach [88] [81], drugs have been tested on the three different stop 
codons codified by the aforesaid pathogenic nonsense mutations: UGA (R59X, R134X, 
R550X, S855X), UAG (Q347X) and UAA (E364X). 
Using the Q5 Site-Directed Mutagenesis Kit (NEB), nonsense sites were introduced in 
the pEGFPC1-hCDKL5107 construct codifying for the human CDKL5 isoform weighting 
107 kDa fused to EGFP at the N-terminus (Fig. 6A) [52]. Moreover, since a different 
amino acid might be introduced at the PTC site after read-through, we mutagenized the 
aforementioned cDNAs to obtain the most probable full-length protein that may be 
produced after drug treatment. We thus generated constructs carrying a tryptophan at the 
TGA nonsense sites (Fig 6A, R59W, R134W, R550W, S855W) whose non-polar nature 
dramatically contrasts with the polar nature of original arginine [91]. Concerning the two 
derivatives containing a TAG (Q347X) and TAA (E364X) PTC, glutamine represents the 
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most probable residue introduced by read-through [91]. Since for the Q347X mutant, the 
read-through product will have a high chance to reproduce the WT amino acidic 
sequence, we did not generate any full-length derivative. On the contrary, the E364 
residue will be probably substituted with an amino acid (glutamine) that carries quite 
different chemical properties; considered that this PTC is predicted to be difficult to 
rescue we decided to postpone the production of a full-length “suppressed” E364Q 
derivative after having tested read-through. 
 
All constructs were verified by Sanger sequencing and the correct size of the proteins 
were verified by Western Blot (WB, Fig. 6B). We could thus confirm that all proteins 
have the expected molecular weight given by the EGFP portion (~27 kDa) fused to the 
specific cDNA:  WT and R/S-W proteins ~134 kDa, R59X ~34 kDa, R550X ~88 kDa, 
R134X ~42 kDa, Q347X ~65 kDa, E364X ~67 kDa (Fig. 6B). 
At the subcellular level, WT CDKL5 is localised both into the nucleus and cytoplasm; on 
the contrary, truncating or missense mutations can alter the nucleo-cytoplasmic 
distribution of the kinase and its capability to give rise to dots [54] [52].  
In order to understand whether read-through products might retain WT features although 
containing a missense mutation, tryptophan-substituted proteins were analysed by 
immunofluorescence (IF). As shown in Fig. 6C, WT protein is equally distributed 
between the nucleus and the cytoplasm and has a dotted staining in both compartments 
(Fig. 6C, panels a and b); the nature of this dots is not defined yet. W-containing proteins 
exhibit a similar distribution and are capable of forming dots (Fig. 6C, panels c-d-e and 
f). These preliminary results led us to hypothesize that read-through products could have 
a proper subcellular localisation and therefore possibly a correct functionality and 
capability to interact with partners, thus, encouraging further studies. 
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Figure 6. Full-length CDKL5 derivatives containing a missense mutation possibly caused by PTC 
suppression maintain a proper subcellular distribution. 
A) Schematic representation of the GFP-tagged hCDKL5 derivatives generated by site-directed 
mutagenesis. On the left is highlighted the introduced stop codon. For constructs containing a TGA 
premature stop codons, full-length derivatives containing a W instead of the PTC were generated. In 
blue is represented the N-terminal catalytic domain, while in white is shown the C-terminal tail.  
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NA: Not Available. NSC: Natural Stop Codon.  
B) WB (10% SDS-PAGE) analysis assessing the expression and correct size of the generated constructs. 
Protein lysates were isolated from HeLa cells transfected for 24hrs with WT or mutated constructs. 
CDKL5 derivatives were revealed using anti-GFP antibody. 
C) IF analysis of HeLa cells transfected with WT and mutated CDKL5 cDNAs containing the W-missense 
mutation. For each CDKL5 derivative, the upper row shows the DAPI stained nuclei (blue), the middle 
row shows the GFP-expressing cells (green) and the lowest row shows the merge between DAPI and 
GFP. Images are representative of the subcellular distribution of proteins analysed in at least 60 cells 
per CDKL5 derivative (n=3). Magnification 100x, scale bar 30 µm. 
 
3.2 Truncated proteins may aberrantly localise in different 
subcellular compartments 
 
As already mentioned, alterations in CDKL5 have been correlated to its impaired 
shuttling between nucleus and cytoplasm [52] [54]. For this reason, we have decided to 
analyse the subcellular distribution of truncated proteins; in fact, the identification of an 
overt phenotype would facilitate the visualization of an effective read-through process, 
restoring CDKL5 proper behaviour. 
We have thus analysed by IF the localisation of the premature truncated derivatives 
transfected in HeLa cells (Fig. 7A).  
As expected, the analyses revealed a different subcellular distribution of truncated GFP-
tagged proteins that seems to depend on the position of the nonsense mutation. Most 
premature stop codons (R59X, R134X; Fig. 7A, panels d and e) determine the generation 
of chimeras in which the GFP portion is largely predominant; accordingly, the subcellular 
distribution of these mutants well overlapped with that one exhibited by GFP (Fig. 7A, 
panels c). Analogously, mutants carrying nonsense sites in the beginning of the C-
terminal tail (Q347X, E364X; Fig. 7A, panels f and g) revealed a similar localisation 
respect to GFP, suggesting that the presence of NLS1 is not sufficient to determine a 
nuclear accumulation. On the contrary, R550X protein seems to be enriched into the 
nucleus (Fig. 7A, panels h). Finally, in cells expressing the S855X mutant (Fig. 7A, panels 
i) the nuclear DAPI remained quite evident below the green signal of the GFP-tagged 
protein; this evidence could indicate that NES signal may be sufficient to export the 
protein in the cytoplasm despite the presence of the two nuclear localisation signals 
(NLS1 and NLS2).  
These results are indicative of a different distribution between the nucleus and the 
cytoplasm of the diverse derivatives; however, we do realize that in the future we will 
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have to perform confocal analyses or fractionation experiments (see below) to properly 
interpret the obtained results.  
In addition to altered localisation, truncated proteins seem to have lost the capability to 
form dots. 
Similar results were obtained in HEK293T cells; however, the GFP-CDKL5 R134X 
mutant manifested the formation of an aggregate close to the nucleus that clearly 
distinguishes itself from other constructs (Fig. 10A, c). 
 
To better understand the entity of the alterations in the subcellular localisation suggested 
by IF data, we performed WB analyses using fractionated cell extracts.  
As shown in Fig. 7B and C, the analysis of nuclear and cytoplasmic signals seems to 
confirm that the alteration in the subcellular distribution is dependent on the position of 
the premature stop codon. Indeed, mutants containing a PTC in the N-terminal domain 
(R59X, lanes 5-6; R134X, lanes 8-9) and at beginning of the C-terminal tail (Q347X, 
lanes 11-12) are clearly enriched in the cytoplasmic fraction. Such result is also confirmed 
by the quantification of the ratio between nuclear and cytoplasmic fraction compared to 
WT arbitrarily set to 100% (Fig. 7C). 
On the contrary, although the WB of the R550X derivative suggested a slight enrichment 
into the nucleus, this result was not confirmed by quantifying several experiments. 
Eventually, whereas the S855X protein shows a significant reduction of accumulation in 
the nuclear compartment with respect to the WT kinase, the presence of the C-terminal 
E364X and R550X PTCs determines only a tendency in such reduction.  It is worthwhile 
to mention that the observed high variability is probably well justified by the knowledge 
that CDKL5 subcellular distribution seems to be affected by the cell type, cell cycle and 
cell physiological conditions. 
 
Altogether, these data confirm that truncating mutations can affect CDKL5 nucleo-
cytoplasmic distribution [54] [52] and the identified phenotypes could be used as readout 
of rescued WT features after read-through. 
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Figure 7. Nucleo-cytoplasmic distribution of almost all truncated GFP-CDKL5 proteins differ from 
WT GFP-CDKL5. 
A) IF assay of HeLa cells transfected with different PTC-containing or WT constructs for 24hrs. Staining 
was performed using DAPI (blue, upper row) and anti-GFP (green, middle row); the analysis was 
performed on at least 60 cells per condition (n=3). Magnification 100x, scale bar 30 µm. 
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B) WB analysis of the subcellular distribution of fractionated HEK293T cells overexpressing GFP-tagged 
WT or truncated derivatives. The same volume of nuclear and cytoplasmic fraction, corresponding to 
an identical number of cells, was analysed.  
The upper panel shows the CDKL5 specific bands identified by anti-CDKL5 (WT, R550X, S855X) or 
anti-GFP (R59X, R134X, Q347X, E364X) antibodies; in the middle and lower panels, the quality of 
fractionation was assessed testing the distribution of MeCP2 and a-tubulin, used as nuclear and 
cytoplasmic markers, respectively.  
Tot: total extract, N: nuclear extract, C: cytoplasmic extract. 
C) Graphical representation of the subcellular distribution (nucleus/cytoplasm) of truncated derivatives 
with respect to WT GFP-CDKL5. Nucleo-cytoplasmic distribution of WT was arbitrarily set to 100% 
and nucleo-cytoplasmic distribution of truncated derivatives was expressed as values relative to WT. 
The error was expressed as SEM; the significance was evaluated by one-way ANOVA followed by 
Bonferroni’s post hoc test (* p < 0.05, ** p < 0.01, *** p < 0.001); n³3 
 
3.3 Aminoglycoside drugs are able to suppress CDKL5 UGA 
stop codons in a dose-dependent manner 
 
The large portion of human genetic diseases that can be caused by nonsense mutations in 
specific genes have pushed up different studies analysing the possibility to suppress PTCs 
through chemical compounds. In particular, aminoglycoside read-through activity 
mediated by gentamicin or G148 has been extensively examined. 
We thus started testing whether treatment with different doses of gentamicin or G418 
would promote read-through of R59X and R134X mutants causing a UGA premature 
stop codon. 
As shown in Fig. 8, in absence of aminoglycosides no full-length product was generated, 
while both drugs partially suppressed R59X (Fig. 8A, B) and R134X (Fig. 8A’, B’) PTCs 
causing the production of a full-length CDKL5. Read-through efficacy was strictly 
dependent on the drug dose; in particular, for both mutants an evident signal was 
detectable when cells were treated with 500-2000 µg/ml of G418 (Fig. 8A, 8A’ lanes 7-
9) or the same dose of gentamicin (Fig. 8A, 8A’ lanes 7-9). However, depending on the 
specific mutation and the specific experiment, lower drug doses could induce sufficient 
amounts of full-length CDKL5 to be detected above the background in our experimental 
conditions (as an example see panel B’, lanes 5 and 6). As expected, WT protein size was 
not affected by treatment with the maximal dose (2000 µg/ml) of G418 (Fig. 8A, lane 2; 
Fig. 8C, lanes 10-11-12) or gentamicin (Fig. 8B, B’, lane 2) confirming that these drugs 
do not alter the normal arrest of protein synthesis.  
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Figure 8. High doses of G418 and gentamicin mediate PTC suppression. 
WB (8% SDS-PAGE) analysis of protein lysates from HEK293T cells transfected with R59X (A, B, C) or 
with R134X (A’, B’, C) and treated with G418 (A, A’) or gentamicin (B, B’) at the indicated doses for 
24hrs or with G418 (2000µg/ml) for 16, 24 and 48hrs (C). Cells were collected in Sample buffer and the 
same number of cells transfected with the truncated constructs or half of this number from samples 
transfected with the WT construct were loaded on the gel. Immunoreactivity was detected using anti-GFP 
and anti-CDKL5 antibodies. GFP antibody binds to the amino-terminus of the expressed chimera; 
a-CDKL5 binds a C-terminal epitope (a.a. 636-758). In C, a-tubulin was used as loading control. 
Arrowheads denote the full-length GFP-CDKL5 protein; arrows highlight each specific mutant form of 
GFP-CDKL5. n=3 
–: untreated cells; +: treated cells with 2000 µg/ml of G418/gentamicin. 
 
These analyses indicate that both drugs are similarly able to induce read-though and that 
the best efficiency is reached at the higher concentrations. Indeed, although gentamicin 
has resulted to be more efficient at lower concentration depending on specific mutant 
(Fig. 8 B’, lanes 5 and 6), this trend was not confirmed in all experiments. On the contrary, 
our experiment shown in Fig. 10 suggests that high doses of G418 have a more robust 
read-through percentage on all mutants that we identified as read-through sensitive; for 
such reason, we proceeded performing most analyses with G418. 
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Then, we assessed the influence of incubation time on read-through. As shown in Fig. 
8C, the study of the response to G418 at different time points revealed that most PTC 
suppression has already occurred in 16 hours of treatment while prolonged exposure did 
not determine any increase of the full-length signal. 
 
3.4 Read-through occurs at different CDKL5 PTC types but it 
is probably dependent on the position of the PTC 
  
In the context of PTC suppression two main factors should be considered: the identity of 
PTC and its nucleotide context. Different studies have indicated that UGA is the easiest 
stop codon to be read-through [88] [81], while a cytosine or uridine immediately 
downstream the stop codon (+4 position) give rise to the highest rate of PTC suppression 
[91]. In addition, gentamicin read-through was found to be more efficient when a uridine 
is present at -1 position [92]. 
Concerning CDKL5-related pathologies, only about 30% of nonsense mutations codify 
for UGA stop codon, while about 40% and 30% give rise to UAG and UAA PTCs, 
respectively. Understanding whether PTC suppression can occur at different PTC types 
is thus mandatory for the treatment of CDKL5 patients carrying nonsense mutations. 
The analysis of the nucleotide context of chosen PTCs revealed that none of them has the 
most favourable surrounding sequence for read-through (Fig. 9A’, B’, C’). Nevertheless, 
G418 mediated the read-through of all PTC types: UGA (Fig. 9A, lanes 6-7-8), UAG 
(Fig. 9B, lane 4) and UAA (Fig. 9B, lane 6). The only PTC studied that was not 
suppressed neither by gentamicin (Gent.) or G418 causes the generation of a truncated 
protein containing 855 amino acids (S855X mutant, Fig. 9C). Such result was unexpected 
since S855X mutant codifies for a UGA stop codon and the surrounding context is similar 
to the other PTCs analysed. Being so close to the natural stop codon, we hypothesize that 
the S855 PTC might exploit the close 3’-poly-(A) tail for the recruitment of releasing 
factors to the poly-(A) binding proteins, thus increasing the efficiency of translation 
termination and, therefore, significantly limiting the efficacy of read through drugs. 
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Figure 9. G148 facilitates the suppression of different PTCs.  
WB (8% SDS-PAGE) assays of samples extracted from transfected HEK293T cells and treated with G418 
(2000 µg/ml, A, B, C) or gentamicin (2000 µg/ml, C) for 24hrs. Cells were transfected with TGA- (R59X, 
R134X, R550X, S855X; A, C), TAG- (Q347X) or TAA- (E364X) containing constructs (B) and collected 
in Sample buffer; the same number of cells transfected with the truncated constructs or half of this number 
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from samples transfected with the WT construct were loaded on the gel. Immunoreactivity was detected 
using anti-GFP or anti-CDKL5 antibodies. n³3 
Arrowheads identify the full-length GFP-CDKL5 protein; arrows show specific truncated mutant of GFP-
CDKL5. A’, B’, C’ show the nucleotide context of the different PTCs (blue) together with the best 
nucleotide context for read-through (red) [91] [92] 
–: untreated cells; +: treated cells with 2000 µg/ml of G418 or gentamicin (Gent.) 
 
 
3.5 Aminoglycosides differentially suppress CDKL5 PTCs 
 
It is well known that the efficiency of aminoglycoside-derived read-through is dependent 
on the stop codon type. We thus proceeded trying to establish the efficiency of gentamicin 
and G418 to suppress the PTCs of the already described CDKL5 mutants. In particular, 
we focused on R59X, R134X and R550X mutants that in previous WBs (Figs. 8 and 9) 
had demonstrated a good recovery of the full-length protein.  
To this purpose, we used IF experiments with the aim of exploiting an anti-CDKL5 
antibody that by recognizing a C-terminal epitope permits to detect only full-length 
CDKL5 derivatives. Indeed, in the absence of aminoglycosides only cells transfected with 
the WT construct permitted to detect the CDKL5 signal (Fig. 10A, a’; red cells) while, as 
expected, cells transfected with the truncated derivatives did not show any red signal (Fig. 
10A, b’, c’, d’).  
Importantly, a (presumably) full-length CDKL5 could be identified after G418 treatment 
(Fig. 10A, f’, g’, h’; red cells). By comparing the subcellular distribution of the read-
through red products with respect to the WT protein, it appears that rescued molecules 
well phenocopy CDKL5. On the contrary by comparing red and green signals, we found 
that the two signals do not coincide, possibly because most of GFP signal is given by 
truncated derivatives. Furthermore, the strong variability in subcellular distribution of 
WT CDKL5 transfected in HEK293T cells together with the intrinsic features of such 
cells (i.e. huge nucleus and little cytoplasm) did not allow us to well compare by IF the 
subcellular distribution of the diverse mutants with respect to WT CDKL5.  
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Figure 10. Aminoglycoside read-through efficiency varies according to the specific R-X mutant.  
A, B)  IF analyses of HEK293T cells transfected with WT, R59X, R134X or R550X mutants and treated 
with 2000 µg/ml of G418 (A, B) or gentamicin (B) for 24hrs. In untreated cells, GFP signal allows to 
identify only WT or truncated proteins. To evaluate GFP-R134X signal the brightness was strongly 
increased. CDKL5 signal is specific for full-length proteins (WT or read-through products; antibody 
epitope: a.a. 636-758). In A, merge panels result from overlapping of GFP (green), CDKL5 (red) and 
DAPI (blue); in B from GFP (green), CDKL5 (red). Magnification 40x (A) or 20x (B), scale bar 30 
µm. n=3 
C)      Graphical representation of gentamicin (blue) and G418 (red) read-though efficiency. The percentage 
of read-through was determined by counting full-length CDKL5 positive cells over GFP positive cells. 
The error was expressed as SEM; the significance was evaluated by Student’s t test (* p < 0.05, ** p 
< 0.01, *** p < 0.001); n=3 
 
However, by overlapping GFP-R-X (green) and full-length CDKL5 signals after 
treatments (red; Fig. 10B, b’’, c’’, e’’, f’’, h’’, i’’), it emerged that not all transfected cells 
generate detectable full-length CDKL5 derivatives and such result depends on the 
specific mutation and read-through drug. In fact, by quantifying the results, calculating 
the percentage of read-through CDKL5 positive cells (red) over transfected cells 
expressing the truncated derivatives (green), we found that G418 more strongly induces 
read-through of selected PTC sites (Fig. 10C). In particular, the suppression of R134X 
stop codon appeared particularly efficient (>75%), followed by R550X (>35%) and R59X 
(>25%).  
By observing the IF results of R550X and R59X mutants, we can state that some cells 
were more susceptible to treatment, while others did not respond at all or produced a too 
little amount of full-length protein to be detected above background.  
Concerning the R134X mutant we have observed that its transfection leads to very few 
cells weakly expressing it (in Fig.10B compare panel d with panels a and g), its frequent 
accumulation in perinuclear aggregates (Fig. 10A, c) and a low signal in WB presenting 
several degradation products (see WB in Figs 6B, 7B, 8A’, 8B’, 11A’, 11B’, 13A). 
Moreover, cells co-transfected with R134X and GFP expressed the truncated construct at 
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a low level in spite of equal expression of GFP (data not shown) therefore demonstrating 
that this phenotype is not caused by transfection deficiency and/or cell lethality. We 
hypothesize that the herein observed highly efficient read-through might simply reflect a 
stabilization of the full-length CDKL5. 
 
3.6 PTC124 and GJ072 are not able to induce read-through of 
selected CDKL5 premature stops 
 
The results described above demonstrate that in our experimental conditions we can 
observe an effective read-though of CDKL5 PTCs at high aminoglycoside doses, known 
to be toxic [81]. 
This consideration led us to test the efficacy of alternative compounds and, in particular, 
of non-aminoglycosides. We have verified whether different doses and incubation times 
of PTC124 or GJ072 may promote the read-through of CDKL5 R59X or R134X mutants. 
 
 
 
Figure 11. PTC124 and Gj072 do not induce read-through. 
WB (8% SDS-PAGE) analyses of protein lysates from HEK293T cells transfected with R59X (A, B) and 
R134X (A’, B’) truncated derivatives and treated with PTC124 (A, A’) or GJ072 (B, B’) for 24hrs; 
increasing drug doses were used as indicated in the figure. Cells were collected in Sample buffer and the 
same number of cells transfected with the truncated constructs or half of this number from cells transfected 
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with the WT construct were analysed. Immunoreactivity was detected using anti-GFP for R59X and R134X 
truncated proteins or anti-CDKL5 for WT and full-length read-through derivatives. n=3 
Arrowheads indicate the full-length GFP-CDKL5 protein; arrows identify each specific mutant form of 
CDKL5.  
–: untreated cells (DMSO at the maximal dose used with the highest drug concentration); G418: treatment 
with 2000 µg/ml of G418. 
 
As shown in Fig. 11A, A’, PTC124 at any dose (lanes 3 to 6) was not able to give rise to 
full-length GFP-CDKL5, while a full-length product was detectable after G418 treatment 
(Fig. 11A’, lane 7); the same result was obtained administering GJ072 (Fig. 11B, lanes 6 
to 8; Fig. 11B’ lanes 3 to 5). These results were obtained either after 24 hours (Fig. 11) 
or 48 hours (not shown) of treatment. Moreover, in GJ072 experiments a higher dose of 
30 µM was used, but cell toxicity became evident after 24 hours (data not shown).  
These experiments demonstrate that, at least in our experimental conditions, PTC124 and 
GJ072 show no efficacy for CDKL5 PTC suppression, therefore supporting previous 
published data questioning PTC124 capability to facilitate read-through [141] [140, 157] 
[146]. In future studies, we will certainly test whether cell lines can affect the sensitivity 
to specific read-through drugs.  
 
3.7 CDKL5 subcellular localisation can be rescued after read-
through 
 
As already stated, the generation of a full-length product after read-through does not 
guarantee a proper functionality of rescued proteins. Thus, to investigate whether read-
through GFP-CDKL5 proteins well mimic the WT protein, we started analysing the 
subcellular distribution of read-through products. 
Nucleo-cytoplasmic localisation was analysed by WB of fractionated extracts derived 
from transfected and G418-treated HEK293T cells. 
As shown in Fig. 12, the read-through products can rescue an appropriate subcellular 
distribution but this capability seems to depend on the specific nonsense mutation. 
Indeed, the ratio between nuclear and cytoplasmic fraction relative to WT CDKL5 
(arbitrarily set to 100%) revealed that full-length proteins derived from the suppression 
of R59X and R134X PTCs showed a recover of the phenotype. Importantly, R59X and 
R134X truncated proteins display an altered subcellular distribution both in the absence 
(truncated -) or in the presence (truncated +) of G418 confirming, as expected, an 
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enrichment in the cytoplasmic fraction. On the contrary, the read-through of C-terminal 
PTCs did not restore a correct nuclear-cytoplasmic distribution. Indeed, Q347X full-
length derivative maintained a significantly different sub-cellular distribution compared 
to the WT although the cytoplasmic enrichment is reduced respect to the truncated Q347X 
protein. Vice versa, the subcellular distribution of the R550X truncated protein was 
comparable to WT, while the product of its read-through got significantly different. 
 
All in all, these results indicate that after read-through a rescue of a proper subcellular 
distribution is possible but, as expected, the position of PTC could be critical. In 
particular, the introduction of a missense mutation in the C-terminal tail of CDKL5 may 
hinder a proper localisation of CDKL5. 
 
 
 
Figure 12. Read-through derivatives can have a proper nucleo-cytoplasmic distribution. 
Graphical representation of the subcellular distribution (nucleus/cytoplasm) of truncated and read-through 
derivatives compared to WT. Nucleo-cytoplasmic distribution of WT was arbitrarily set to 100% (dotted 
line) and nucleo-cytoplasmic distribution of truncated derivatives was expressed as values relative to WT. 
The error was expressed as SEM; the significance was evaluated by one-way ANOVA followed by 
Bonferroni’s post hoc test (* p < 0.05, ** p < 0.01, *** p < 0.001); n³3 
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3.8 Read-through derivatives are impaired in their catalytic 
activity 
 
We proceeded by testing to what extent read-through full-length CDKL5 proteins have 
rescued their proper catalytic activity. 
As already mentioned the catalytic domain of CDKL5 resides in the protein N-terminus, 
while C-terminal tail has been reported to negatively regulate the kinase activity [55]. 
Indeed, C-terminal truncated proteins display a higher catalytic activity than full-length 
CDKL5 [55] [54], possibly suggesting that kinase activity of CDKL5 should be finely 
regulated.  
For these reasons, we have considered necessary to establish whether full-length CDKL5 
derivatives may recover an appropriate kinase activity by evaluating the TEY motif auto-
phosphorylation. As other members of the CMGC family, the dual TEY motif 
phosphorylation at threonine and tyrosine residues is necessary for maximal activation 
[158] [55] [54]. Accordingly, no TEY auto-phosphorylation can be observed in the 
“kinase-dead” CDKL5 K42R mutant, a construct carrying a missense mutation in the 
ATP binding site that impairs the capability to bind ATP and transfer the phosphoryl 
group to the substrate [55] [54].  
TEY phosphorylation level of each read-through mutant was thus assessed by dividing 
the signal obtained using an anti-phospho-ERK1/2 (Thr 202/Tyr 204) to total CDKL5 
and comparing such ratio to the one of WT samples arbitrarily set to 100. 
As shown in Fig. 13 A, A’, a discrete auto-phosphorylation signal can be detected, 
suggesting that full-length derivatives derived from the read-through process own some 
catalytic activity (upper panel, lanes 4-6-8); however, they are clearly hypomorphic (Fig. 
13A’). It is worth noting that the evaluation of TEY phosphorylation in R59X and R134X 
truncated protein cannot be possible since such motif is located downstream the PTCs 
(a.a. 169-171); further, for these mutants we could not exploit the CDKL5 antibody 
(recognising a.a. ~370-520) for normalization. On the contrary, preliminary experiments 
indicated that R550X kinase activity seems to be similar to WT (data not shown). 
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Figure 13. Read-through proteins appear to have an hypomorphic catalytic activity. 
A, B)  WB (8% SDS-PAGE) assays evaluating the auto-phosphorylation of the TEY motif through an 
anti-phospho-ERK antibody (upper panel, arrowhead; * indicates an aspecific product). HEK293T 
cells were transfected with WT, R59X, R134X or R550X constructs and treated with G418 (2000 
µg/ml) for 24hrs (A) or WT, R59W, R134W or R550W constructs (B). Full-length CDKL5 and 
R550X truncated proteins were detected using an anti-CDKL5 antibody, the remaining truncated 
proteins with anti-GFP antibody. 
Arrowheads identify the full-length GFP-CDKL5 protein; arrows show specific truncated mutant 
of GFP-CDKL5. 
–: untreated cells; +: treated cells with 2000 µg/ml of G418 
A’, B’) Graphic representation of the mean relative phosphorylation normalised to CDKL5 signal of 
different experiments. TEY phosphorylation of WT was arbitrarily set to 100 (dotted line) and 
TEY auto-phosphorylation of read-through products was expressed as values relative to WT. The 
error was expressed as SEM; the significance was evaluated by Student’s t test (* p < 0.05, ** p < 
0.01, *** p < 0.001); n=3 
 
To understand whether the possible amino acid substitution at PTC sites can be 
responsible for the observed reduced catalytic activity, we analysed the auto-
phosphorylation signal of W-containing mutants. As shown in Fig. 13B, B’, only R59W 
protein has revealed a significant lower auto-phosphorylation activity, while R134W and 
R550W derivatives were comparable to WT.  
These results suggested that read-through products can be catalytically active and that, in 
accordance with our hypothesis, the position of PTCs and the type of amino acid inserted 
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can influence the extent of their activity. Accordingly, analysing dbSNP database no 
missense variant can be found at 59, 134 positions, possibly suggesting that the complete 
recovery of kinase activity may be obtained only if arginine will be introduced at analysed 
PTC sites. On the other hand, a possibly non-pathogenic missense variant introducing a 
glutamine at 550 position can be found (rs745508309) indicating that amino acid 
substitutions are probably tolerated at this site.  
 
3.9 Read-through full-length derivatives can rescue the 
impaired neuronal branching in transfected Cdkl5-null 
neurons 
 
To understand whether the generated read-through protein may be sufficient to rescue the 
pathological phenotype associated with CDKL5 deficiency, we tested G418 in transfected 
Cdkl5-null neurons.  
We started evaluating cell viability of cortical neurons after G418 treatment through MTT 
assay. As shown in Fig.14A, the MTT reduction normalised to controls has revealed that 
about 90% of neurons are viable after G418 treatment at different doses. Considering that 
in HEK cells a good level of full-length CDKL5 was detected at 500 µg/ml dose (Fig. 8), 
we started these preliminary studies by testing such concentration in transfected Cdkl5-
null neurons.  
Cdkl5 depletion is associated with reduced dendritic arborisation [58] [73] [70]; we thus 
decided to analyse whether read-through of a PTC mutant could rescue a proper neuronal 
branching in Cdkl5-null neurons. 
To this purpose, cortical neurons from E15 Cdkl5Y/- mouse embryos were prepared and 
transfected at DIV12 with WT GFP-CDKL5 or GFP-CDKL5 R134X. The mutant was 
chosen for its strong susceptibility to read-through. 24 hours later, neurons were treated 
with G418 and fixed at DIV14, when functional synapses can be found [50]. Using anti-
CDKL5 antibodies recognising C-terminal regions of the kinase (Sigma: a.a. 636-758 or 
Santa Cruz: a.a. ~370-520), no specific CDKL5 signal could be detected above the 
background by IF. However, such observation does not exclude the generation of small 
amounts of the full-length kinase; in fact, exploiting Cdkl5-null brains, we have already 
demonstrated that by IF no CDKL5 antibody is able to distinguish the protein above the 
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background when the kinase is present (as testified by western blot) but very low in 
abundance.  
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Figure 14. Neuronal defects can be rescued after G418 treatment. 
A)  MTT assay assessing viability of neurons treated with indicated doses of G418 for 24hrs. Absorbance 
of treated samples was normalized dividing by values obtained from control neurons. n=2 
B)     Representative images from DIV14 cortical neurons transfected with WT GFP-CDKL5 (a, b) or GFP-
CDKL5 R134X (c, d) constructs and treated with 500 µg/ml G418 for 24hrs. Magnification 40x, scale 
bar 30 µm. n=2 
B’)    Graphical representation of neuronal branching evaluation in transfected and treated neurons (B). The 
error was expressed as SEM; the significance was evaluated by two-way ANOVA followed by 
Bonferroni’s post hoc test (* p < 0.05, ** p < 0.01, *** p < 0.001); n=2 
 
 
The possibility that some read-through CDKL5 is present appears to be supported by a 
phenotype amelioration in neurons transfected with R134X construct and treated with 
G418 (Fig. 14B). Indeed, by counting neurons with low, intermediate or high number of 
branches, we can observe that the expression of WT GFP-CDKL5 seems to promote 
neuronal branching of otherwise null neurons (Fig. 14B, a-b, and B’). On the contrary, 
neurons expressing the R134X derivative reveal the presence of a reduced and shorter 
number of neurites (Fig. 14B, c, and B’). On the other hand, treatment with G418 clearly 
ameliorated the branching defects determining an increase of neurons with more and 
longer neurites (Fig. 14B, d, and B’). 
These results suggest that few amounts of full-length, possibly hypomorphic, CDKL5 
could ameliorate neuronal impairment given by the absence of the kinase.  
Nevertheless, we are aware that to confirm our results we have to test aminoglycosides 
on different PTC-containing constructs and to more deeply analyse their impact on 
neuronal morphology. Moreover, to better evaluate the read-through efficiency in 
neurons we will generate constructs codifying for a C-terminal RFP. 
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4. DISCUSSION 
 
Mutations in CDKL5, a complex gene located on Xp22, have been associated with 
different neurological disorders including the early seizure variant of RTT syndrome 
[32], also known as the Hanefeld variant [29].  
CDKL5 is an ubiquitously expressed serine/threonine kinase localised both in the nucleus 
and cytoplasm of neurons and proliferating cells [54] [52] [57]. Different functions have 
been associated with the kinase according to its subcellular compartment. In the nucleus, 
CDKL5 seems to regulate gene expression through the interaction with DNMT1 [61] and 
MeCP2 [60]. In the cytoplasm, CDKL5 has a role in neural polarisation via the interaction 
with shootin1 [63], in the regulation of cytoskeleton dynamics by association with Rac1 
[51] and IQGAP1 [67], in spine development and synaptic stability by NGL1 
phosphorylation and association with PSD95 [58]. Moreover, we have recently 
demonstrated that in proliferating cells CDKL5 affects cell division via the 
phosphorylation of H2B mediated by HIPK2 [79]. 
The generation of different Cdkl5-null mouse models has permitted to better understand 
CDKL5 functions [64] [65] [66]. However, although epileptic encephalopathy is 
considered the prominent clinical feature of CDKL5-related pathologies, none of these 
models has shown spontaneous seizures and all are characterized by moderate 
phenotypes. 
Although different studies have been published in recent years, CDKL5 roles have not 
been completely elucidated yet. For this reason, no cure exists for CDKL5 patients and 
current treatments are only intended to ameliorate secondary symptoms, in particular 
epilepsy.   
In the brain, CDKL5 expression is finely regulated during development, getting strongly 
induced in early postnatal day (P14) while low levels can be found during embryogenesis 
[52]. Moreover, the kinase expression is modulated in response to stimuli. In fact, 
sustained glutamate stimulation of mature neurons determines a massive proteasome-
dependent degradation of CDKL5 that occurs through extrasynaptic NMDA receptors 
[57]. In addition, neuronal activation quickly induces CDKL5 expression; the increased 
levels are obtained through two main molecular mechanisms: an increase in gene 
transcription and the activation of localised protein synthesis in dendritic fractions. 
Importantly, neuronal maturation influences the extent of this activation. Indeed, while in 
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immature neurons CDKL5 levels remain up-regulated for about 1 hour after KCl 
stimulation, neuronal maturation determines a proteasomal-dependent demolition of the 
kinase and, consequently, the decline to basal levels within few minutes [50]. These 
observations indicate that CDKL5 levels have to be strictly modulated and that both gain 
or loss of functions may alter brain development. Accordingly, patients carrying CDKL5 
duplications have been reported [38]. This evidence leads some concern about the 
possibility to use gene- and protein-augmentative therapies for the treatment of CDKL5 
patients; in fact, both these approaches will not reproduce the subtle regulation of the 
kinase expression. In addition, the large dimension of CDKL5 gene, the absence of 
information about regions involved in mRNA localisation in dendrites and spines and the 
activation of protein synthesis by neuronal depolarization limit the design of the best 
vector. 
We thus reasoned that some CDKL5 patients might benefit from therapeutic approaches, 
tailored in function of the specific genetic lesion.  
In particular, PTC suppression might be a valid therapeutic approach for CDKL5 patients 
carrying a nonsense mutation, accounting for about 15% of all cases described so far. 
Several chemical compounds have been discovered or specifically designed to induce 
read-through and some of them (i.e. aminoglycosides and PTC124) revealed a sufficient 
efficacy to be used in clinical trials; this seems to be particularly promising for nonsense 
CDKL5 patients although the capability of these drugs to cross the BBB is still under 
discussion. BBB permeation is favoured by different factors including lipophilicity and 
reduced molecular dimension of compounds. On the contrary, aminoglycosides are 
hydrophilic molecules with a molecular mass of about 400 Da whose penetration in 
cerebrospinal fluid is low in the absence of meningeal inflammation [159]. However, the 
ability to improve neurological defects by administering two designer aminoglycosides 
promoting read-through, NB54 and NB84, in a nonsense MPS I-H mouse model suggests 
that these drugs could be able to reach brain tissues [156] [123]. Of note, aminoglycosides 
are principally endocytosed in cells via the megalin receptor whose expression has been 
found in different neural cells including astrocytes, oligodendrocytes and neurons [160] 
indicating that such drugs can be uptaken by different cell types in CNS. 
 
In this study, we tried to understand whether nonsense mutations causing the onset of 
CDKL5-related encephalopathy can be suppressed using read-through compounds and 
whether the obtained full-length derivatives exhibit molecular and cellular features 
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largely overlapping with the WT protein. In particular, with these analyses we wanted to 
comprehend i) the efficacy of read-through on different CDKL5 nonsense mutations; ii) 
whether read-through products have the capability to rescue some features of the kinase 
and iii) whether the possible rescue of the phenotype may depend on PTC localisation. 
Considering the distribution of pathogenic missense mutations, we hypothesized that the 
suppression of PTCs located in the catalytic domain would have lower capability to 
recover the kinase properties (catalytic activity and possibly subcellular distribution), 
while the read-through of C-terminal PTCs could generate full-length proteins 
maintaining most of the biochemical and cellular properties of the WT protein. Indeed, 
while several missense mutations within the catalytic domain determine a clinical 
condition, very few if any missense pathogenic mutations have been identified in the C-
terminal region of CDKL5. 
Finally, we wanted to identify the most effective drug, verify the possibility of enhancing 
read-through using non-toxic molecules, and, eventually, evaluate whether the read-
through of nonsense derivatives of CDKL5 exogenously expressed in mouse Cdkl5-null 
neurons would allow the rescue of some typical phenotypes [73] [70]. 
 
To verify our hypothesises and obtain a first indication of the feasibility of our studies, 
we have compared the subcellular distribution of WT protein with truncated and full-
length derivatives characterized by a tryptophan residue at the PTC site; such amino acid 
was chosen because it was found to be frequently inserted at UGA non-sense sites after 
read-through [87]. 
As already mentioned, in proliferating cells WT CDKL5 can be found both in the nucleus 
and the cytoplasm, while different types of mutations can alter its shuttling capability 
between the two compartments [54] [52]. Our analyses indicate that some truncated 
proteins have an altered subcellular distribution (Fig. 7). Conversely, the nucleo-
cytoplasmic distribution of W-containing proteins was comparable to the WT, suggesting 
that the recovery of WT protein features is possible after read-though (Fig. 6). These 
preliminary results have encouraged us to test read-through drugs and to understand 
whether the generated full-length proteins can be functional. 
Transient transfection experiments have permitted to ascertain that aminoglycoside drugs 
can induce full-length protein generation in a dose-dependent manner (Fig. 8), as 
previously observed in several studies [89] [161] [90] [162]. Read-through was evident 
only at high doses of aminoglycosides (Fig. 8) and obtained results suggest that PTC 
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position can be critical for read-through. In particular, we speculate that the proximity of 
a PTC to the poly-(A) tail might facilitate the association between eRF3 and the poly-(A) 
binding proteins, thus reinforcing translation termination and hindering the read-through 
process (Fig. 9) [82]. 
Several studies have indicated that the type of stop codon can be critical for read-through 
and UGA stop site was identified as the most responsive to PTC suppression [88] [89] 
[90] [91]. Our results have shown that G418 is able to facilitate the read-through of 
different PTC types at high doses (Fig. 9) and a higher efficiency at UGA stop codon has 
been confirmed. In fact, although WB analyses allowed us to identify the suppression of 
different types of PTCs (Fig. 9), the signal of full-length CDKL5 can be detectable by IF 
only in cells transfected with UGA constructs (Fig. 10). On the contrary, the 
aminoglycoside treatment of cells expressing Q347X (UAG) or E364X (UAA) constructs 
did not permit the evaluation of full-length derivatives in IF assays. These observations 
may suggest that cells transfected with Q347X or E364X constructs produced such a little 
amount of full-length CDKL5 that could not be detected above the background. 
In addition, the percentage of cells generating full-length CDKL5 over transfected cells 
indicates that G418 is more effective than gentamicin [163] [89] [90] [91] and it 
determines a particularly efficient PTC suppression in our conditions that could vary from 
almost 25% to 75% of transfected cells. The higher percentage of read-through (~75%) 
was found in cells transfected with the R134X derivative and treated with G418. 
However, our transfection experiments performed both in cell lines and in neurons 
demonstrate a lower expression of this mutant with respect to the WT or other PTC-
containing constructs. Currently, we are investigating whether this phenotype might be 
caused by an instable mRNA and/or the activation of NMD. If this would be the case, we 
hypothesize that translation might stabilize the transcript therefore leading to a more 
robust read-through. Interestingly, the description of the clinical features of an R134X 
patient evidences a phenotype similar to other CDKL5 patients, although very severe. In 
fact, seizures started already in the second month of life and are refractory to any 
medication [164]. 
IF analyses permitted to deduce that cells do not uniformly respond to aminoglycoside 
treatment; indeed, some cells seem to not be able to respond or to very less extent than 
others (Fig. 10). To the best of our knowledge, no one has ever addressed whether the 
cell cycle may influence the read-through efficiency. Considering that cells were not 
synchronised, we speculate that cells visibly responding to aminoglycoside treatment 
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might be in a phase immediately before the cell division, when protein synthesis is 
particularly increased. In the future, it would be interesting to understand whether the 
different phases of cell cycle may influence the read-through efficiency by starving cells 
transfected with a destabilised GFP. Considering that neurons have a high rate of protein 
synthesis, it might be relevant to discover that read-through efficacy depends on the rate 
of protein translation.  
In addition, by measuring the fluorescence of the full-length CDKL5 signal from each 
cell, we identified a trend where fluorescence intensity is higher in cells treated with 
gentamicin with respect to G418 (data not shown). This observation may suggest that 
G418 is able to induce read-through in a larger number of cells, while gentamicin 
determines the generation of higher amount of full-length protein but in few cells.  
 
Despite the significant efficiency in read-through facilitation, several studies have 
evidenced a high toxicity associated with the administration of aminoglycoside drugs 
[111] [112] [113]. We have thus tried to understand whether the read-though could be 
induced by alternative compounds, in particular by two non-aminoglycoside drugs, 
GJ072 and PTC124. WB analyses of lysates from transfected and treated cells have 
shown that these drugs are not able to facilitate read-through in our experimental 
conditions (Fig. 11).  
Nevertheless, the inefficacy of PTC124 treatment was not entirely unexpected. Indeed, 
although different reports have indicated its capability to induce PTC suppression [127] 
[128] [129] [130] [131] [132] [133], several preclinical studies have not been able to 
detect read-through products after PTC124 administration [140] [141] [142] [143], [144] 
[145] [146] [147]. However, considering that GJ072 read-through activity was found in 
an in vitro assay and in A-T lymphoblastoid cell-lines from patients carrying ATM 
nonsense mutations, we are going to use different cell types and experimental settings to 
evaluate whether drug inefficacy might be due to our experimental setup. 
Given the negative results obtained with non-aminoglycoside drugs treatments, we tried 
to comprehend whether it was possible to reduce the minimum effective dose of G418 
using the CDX5-1 molecule, a powerful read-through enhancer [118]. Our results 
indicated a slight increase of full-length protein only with high doses of G418 in 
transfected HEK293T cells.  HEK293T is an excellent cell line to be used for transfection 
experiments but we are aware that the drug efficiency might be influenced by the cell 
type. We will thus test CDX5-1 in different cell lines; furthermore, considering that 
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CDKL5 alterations are primarily causative of neurological disorders, in the future we 
want to thoroughly investigate read-through, including CDX5-1 sensitivity, in neurons. 
 
To understand whether CDKL5 read-through products are functional we compared some 
of their molecular and cellular features to those of the WT protein. From IF analyses (Fig. 
10) and fractionation experiments (Fig. 12), it appeared that read-through induced the 
production of full-length proteins whose subcellular localisation well overlapped with the 
WT. On the contrary, truncated proteins displayed an altered subcellular localisation even 
in presence of the read-through drug. Nevertheless, the R550X and Q347X full-length 
derivatives were unable to reach a proper nucleo-cytoplasmic distribution. These results 
suggest that the PTC position can be relevant for the correct localisation of the full-length 
protein and, in contrast with our initial hypothesis, they indicate that read-through of 
PTCs contained in the catalytic domain might be feasible. 
However, the dbSNP database analysis allowed us to identify a non-conservative (R/Q) 
missense mutation at 550 position which is not associated with a clinical condition; we 
cannot thus exclude that variations may be tolerated. On the contrary, no polymorphisms 
or missense mutations can be found at 59, 134 or 347 positions in the dbSNP database.  
By deleting the C-terminal of CDKL5, Mari et al. [60] have identified that the region 
containing amino acids 450-550 is necessary for the association with MeCP2, while 
amino acids 551-650 reinforce such interaction. It would be thus interesting to understand 
whether the suppression of truncated mutants will generate full-length proteins with a 
restored full capability to interact with the methyl-binding protein. 
 
Verifying whether read-through products are catalytically active is also crucial for 
understanding their functionality.  
In the activation loop of CDKL5 is located a TEY motif whose intermolecular auto-
phosphorylation is suggested to be indicative of the enzymatic activity of CDKL5 [54] 
[55]. By analysing the TEY motif auto-phosphorylation emerged that full-length read-
through derivatives only partially recovered the catalytic activity and might, therefore, be 
hypomorphic (Fig. 13); a hypothesis that however remains to be demonstrated. 
Nevertheless, the results from the W-containing full-length CDKL5 derivatives revealed 
that only the amino acid substitution at 59 position is particularly critical for the TEY 
phosphorylation, while R134W and R550W mutants showed a phosphorylation level 
similar to the WT (Fig. 13). These results, as hypothesized, indicate that an amino acid 
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substitution can interfere with the catalytic activity and the type of amino acid and the 
position of PTC can be crucial. Since at premature UGA stop codons,  tryptophan, 
cysteine or arginine are preferably inserted [83] [84] [85] [86] [87], in the future it would 
be interesting to test the consequences on the catalytic activity of having a cysteine as 
missense mutation.  
On the other hand, considering that ribosomal toeprinting studies have proposed a 
protracted ribosomal pausing at PTCs [165] and that the co-translational folding depends 
on the timing of protein synthesis [166], we can speculate that during read-through the 
prolonged ribosomal pausing may alter the folding of the nascent polypeptide possibly 
impairing its catalytic activity and, therefore, justifying the apparently contrasting results 
obtained comparing the catalytic activity of read-through products and W-substituted 
CDKL5 derivatives. 
 
CDKL5 depletion causes a decrease of axon and dendrites length [51], defects in dendritic 
arborisation [73] [70] and neuronal polarisation [63] [67]. Concordantly, by transfecting 
R134X mutant in cortical Cdkl5-null neurons we identified clear neuronal branching 
defects that were ameliorated by G418 administration (Fig. 14). 
Although further studies are necessary to fully understand the PTC suppression efficiency 
in neurons and which morphological and molecular CDKL5-associated alterations can be 
restored by treatment with read-through drugs, our preliminary data suggest that small 
amounts of possibly hypomorphic CDKL5 can greatly improve the phenotypes associated 
with the absence of the kinase. To better understand the read-through efficiency in 
neurons we are planning to generate PTC containing constructs carrying an in-frame C-
terminal RFP and thus to verify whether low doses of read-through drugs are sufficient 
to obtain full-length CDKL5 proteins and, possibly, rescue typical Cdkl5-null neurons. 
Considering the low efficiency of neuronal transfection, lentiviral particles will be 
exploited. 
In the future, it will be also important to study read-through in a more physiological 
system. For this reason, we will test aminoglycoside drugs on knock-in neurons obtained 
from the mouse Cdkl5R59X carrying UGA nonsense mutation at arginine 59 (Jackson 
Laboratory). Complementary, CRISPR/Cas9 directed genome editing will be used to 
generate knock-in neural stem cells carrying different nonsense sites, including those 
studied in this dissertation. 
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Eventually, to verify whether aminoglycoside drugs are able to induce read-through of 
endogenous CDKL5 PTCs, we started performing analyses on heterozygous female 
patients-derived fibroblasts carrying Q347X, E364X and R550X nonsense premature 
codons. WB analyses revealed that the expression of full-length CDKL5 is similar to 
healthy control fibroblasts, therefore suggesting the presence of very few cells expressing 
the mutated allele, rendering thus quite difficult the study of read-through drugs in such 
fibroblasts. 
For future experiments, we believe that male neurons derived from differentiated iPS 
could be more suitable for testing read-through.  
Eventually, the possibility to test read-through on endogenous premature stop codons will 
allow us to identify whether PTCs stimulate the NMD mechanism. The effectiveness of 
read-through can, in fact, be strongly affected by the activation of NMD, a surveillance 
pathway leading to degradation of mRNAs containing PTCs [81]; accordingly, in a 
previous study CDKL5 L42X mRNA was reported to be unstable because of NMD 
activation [37]. Importantly, amlexanox, a drug able to both inhibit NMD and promote 
read-through, has been identified [167]. 
In conclusion, the above data suggest that the read-though strategy may be a promising 
therapeutic approach for CDKL5 patients carrying nonsense mutations. However, 
preclinical studies in mouse models are necessary to establish the extent of phenotypic 
amelioration due to the administration of read-through drugs. Moreover, considering that 
our results indicate that aminoglycoside might be used at high doses, the identification of 
molecules capable to enhance their activity will be fundamental. 
Finally, as for other neurological diseases, the design of drugs capable to efficiently cross 
the BBB or effective strategies for drug delivery will be mandatory for the treatment of 
CDKL5 patients harbouring a premature stop codon.  
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5. MATERIAL AND METHODS 
 
5.1 Plasmids and site-directed mutagenesis 
 
pEGFPC1-hCDKL5107 plasmid codifies for human CDKL5 weighting 107kDa, fused to 
EGFP at N-terminal [52]; it is defined as WT in this dissertation. Such plasmid was 
mutagenised to insert the selected human nonsense sites (175 C>T for R59X, 400 C>T 
for R134X, 1648 C>T R550X, 2564 C>G for S855X, 1039 C>T for Q347X and 1090 
G>T for E364X) or to generate constructs codifying the W-containing proteins at PTCs 
(175 to 177 CGA>TGG for R59W, 400 to 402 CGA>TGG for R134W, 1648 to 1640 
CGA>TGG for R550W, 2564 to 2565 CA>GG). Site-directed mutagenesis was 
performed through Q5 Site-Directed Mutagenesis Kit (New England Biolabs) following 
the manufacturer’s protocol and using specific primers (Table 4). All PCR-generated 
constructs were verified by sequencing. 
 
 Forward primers Reverse primers  
R59X AACGACTTTATGAGAGCTTAAAATG 
 
TCTTTGACTTCTTCATTTTCTTC 
 
R134X TATTGTCCATTGAGATATAAAACCAG 
 
TCATTCTTATGGCACCAG 
 
R550X AAGAAATAACTGAAATGAGGGAACG 
 
CCAGAAGGGCTGAGCAAAG 
 
S855X CCGGCTTCCTGAGATCCCCGC 
 
GTGATTTGAGGCCGAAGAGAGATG 
 
Q347X CAAGGACATCTAGAACCTGAG 
 
CTGTTAGATCTGTGGTGAG 
 
E364X CCCTGCCAATTAAAGCTTCCTAAATGG AGACCTTCGTCAGCCCGG 
 
R59W AACGACTTTATGGGAGCTTAAAATG TCTTTGACTTCTTCATTTTCTTC 
R134W TATTGTCCATTGGGATATAAAACCAG 
 
TCATTCTTATGGCACCAG 
 
R550W AAGAAATAACTGGAATGAGGGAACGC 
 
CCAGAAGGGCTGAGCAAAG 
 
S855W CCGGCTTCCTGGGATCCCCGCT 
 
GTGATTTGAGGCCGAAGAG 
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Table 4. Primers used in site-directed mutagenesis.  
Specific primers have been drawn using NEBaseChanger following the manufacturer’s protocol. 
 
5.2 Antibodies 
 
Antibodies used are the following: mouse monoclonal anti-a-tubulin (Sigma-Aldrich, 
T6074), mouse monoclonal anti-GFP (Roche, 1814460), chicken polyclonal anti-GFP 
(Invitrogen, A10262), rabbit polyclonal anti-phospho-ERK1/2 (Thr 202/Tyr 204, Santa 
Cruz, sc-16982), rabbit polyclonal anti-CDKL5 1 isolated from our lab ([54]; a.a. 301-
751), rabbit polyclonal anti-CDKL5 2 (Sigma-Aldrich, HPA002847, a.a. 636-758), 
mouse monoclonal anti-CDKL5 3 (Santa Cruz, sc-376314, a.a. 222-520). Binding sites 
of GFP, CDKL5 1, 2 and 3 antibodies are shown in Fig. 15. 
HRP-conjugated anti-mouse and anti-rabbit secondary antibodies were purchased from 
Thermo Scientific. DAPI and secondary Alexa anti-mouse 488, anti-chicken 488, and 
anti-rabbit 568 antibodies were purchased from Life Technologies Corporation. 
 
 
 
 
Figure 15. Antibodies binding sites on GFP-CDKL5. 
GFP antibody binds the amino-terminus of the expressed hCDKL5 protein; anti-CDKL5 1 recognizes a C-
terminal region of the full-length protein (a.a. 301-751); anti-CDKL5 2 binds a more C-terminal epitope 
(a.a. 636-758); monoclonal anti-CDKL5 3 was raised against a.a. 222-520 and recognises a region between 
~ a.a. 370 and a.a. 550. In blue is represented the N-terminal catalytic domain, while in white is shown the 
C-terminal tail. 
 
5.3 Cell cultures and transfection  
 
HEK293T and HeLa cells were maintained in DMEM (Dulbecco’s modified Eagle’s 
medium, Sigma Aldrich) supplemented with 10% FBS (Gibco), 1% L-glutamine (Sigma 
Aldrich), 1% penicillin/streptomycin (Sigma Aldrich) at 37°C with 5% CO2 in T75 flasks. 
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Cells were seeded in 6-, 12- or 24-well dishes and transfected when they have reached 
the opportune confluence (approximately 70-80%). Both cell lines, were transiently 
transfected with the constructs using Lipofectamine 2000 (Life Technologies 
Incorporated, following manufacturer’s protocol) or calcium phosphate method. The 
amount of DNA used for transfection varies according to number of cell seeded and 
dishes utilised. Cells seeded in 12-well plates were transfected with a total amount of 1.6 
µg DNA/well and 4µl Lipofectamine/well or 2 µg DNA/well when calcium phosphate 
method was used. 
 
5.4 Drug treatments 
 
Eight hrs after transfection, read-through drugs were added in fresh medium without 
penicillin and streptomycin: 
 
Drug Stock solution Working concentrations 
Geneticin (Gibco) 50mg/ml in H2O 10, 50, 100, 500, 1000, 2000 µg/ml 
Gentamicin (Sigma Aldrich) 50mg/ml in H2O 10, 50, 100, 500, 1000, 2000 µg/ml 
PTC124 (Selleckem) 200mM in DMSO 20, 30, 50, 100 µM 
GJ072 (Ambinter) 10mM in DMSO 10, 20 µM 
 
Table 5. Drug tested in the different experiments. 
The powders were dissolved using the shown vehicles (H2O or DMSO) and stored at -20°C or -80°C. Drugs 
were diluted at the indicated working concentrations in DMEM supplemented with 10% FBS and 1% L-
glutamine. 
 
Cells were treated for 16, 24 or 48 hrs with the drug or vehicle. At selected time point, 
cells were collected in 1X PBS (Phosphate Buffered Saline) for fractionation experiment, 
in Sample buffer or lysis buffer for Western blot analysis or fixed in 4% PFA 
(Paraformaldehyde in 1X PBS) for immunofluorescence. 
 
5.5 Western Blot  
 
Cells were lysed using Sample or lysis buffer (50mM Tris HCl pH8, 150mM NaCl, 2mM 
EDTA, 1% Triton X-100, 1mM DTT) supplemented with protease inhibitor cocktail 
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(PIC, Sigma Aldrich) and sonicated for 10 s at 30% amplitude. Lysates were maintained 
on ice for 30 min and then clarified by centrifugation at 14000 rpm for 15 min. Total 
protein content was measured by colorimetric Bradford assay. Samples were heated at 
95°C for 5 min or, to preserve phosphorylations, at 70°C for 10 min. Proteins were 
separated on a 10% or 8% SDS-PAGE under reducing conditions and then 
electrophoretically transferred to a nitrocellulose membrane (Biorad). Blotting was 
verified through ponceau staining and membranes were saturated for 1 h at room 
temperature using 5% non-fat dry milk in TBS-T (20mM TrisHCl pH 7.5, 150mM NaCl, 
0.2% Tween). Blots were incubated with primary antibodies overnight at 4°C or 1h at 
room temperature in mild shaking (Table 6), washed in TBS-T and incubated with 
appropriate secondary HRP-conjugated antibody (1:10000 in 5% non-fat dry milk in 
TBS-T) for 1 h at room temperature. After incubation with secondary antibody, 
membranes were extensively washed with TBS-T and finally immunocomplexes were 
visualized by chemiluminescence using the ECL kit (Genespin) by the Uvitec instrument 
(Cleaver Scientific). 
Densitometric analysis of the immunoblot was performed using Uvitec software. The 
mean value of the control group was set to 1.0 and the data of treated and/or mutated 
samples were expressed as percentage of controls.  
 
Antibody Dilution Incubation time 
anti-a-tubulin 1:10000 in 5% non-fat dry milk TBS-T 1 h at room temperature 
anti-GFP 1:1000 in 5% non-fat dry milk TBS-T overnight at 4°C 
anti-CDKL5 1 1:1000 in 5% non-fat dry milk TBS-T overnight at 4°C 
anti-CDKL5 2 1:1000 in 5% non-fat dry milk TBS-T overnight at 4°C 
anti-CDKL5 3 1:1000 in 5% non-fat dry milk TBS-T overnight at 4°C 
anti-phospho-ERK1/2 1:300 in 5% BSA TBS-T overnight at 4°C 
 
Table 6. Antibodies used in WB experiments. 
Nitrocellulose membranes were incubated with the opportune antibodies as indicated in the table. 
 
5.6 Immunofluorescence 
 
For immunofluorescence (IF) assay, cells were seeded on slides coated with 1 mg/ml 
poly-L-lysine hydrobromide (Sigma Aldrich) to allow the cell adhesion of neurons and 
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HEK293T cells. HeLa cells did not require coating. At selected time point (24 hrs or 32 
hrs after transfection), cells were washed with 1X PBS and fixed in 4% PFA for 20 min 
at room temperature. For CDKL5 staining, cells were permeabilised overday using 
blocking solution (5% horse serum, 0.2% Triton X-100 in 1X PBS) and thus incubated 
with primary antibody (anti-CDKL5 2, 1:500 in blocking solution) overnight at 4°C. 
Slides were washed for several times with 1X PBS and incubated with Alexa anti-rabbit 
568 secondary antibody for 1 h at room temperature. After washes, DAPI (1:1000 for 10 
min; Life Technologies Incorporated) staining was performed and slides were mounted 
using Fluoromount-G (eBioscience). Analyses and acquisition were performed using a 
NikonEclipse Ni upright microscope, while cell counting was done using ImageJ 
(http://rsbweb.nih.gov/ij/). When required, images were adjusted in brightness and 
contrast using Adobe Photoshop. 
 
5.7 Subcellular fractionation 
 
For fractionation experiments, HEK293T cells were seeded in 6-well plates 40 hrs before 
transfection that was performed at 70-80% of confluence. 24 hrs after G418 
administration, cells were collected in 1X PBS and pelleted at 1000g for 5 min at 4°C. 
Cells were lysed in hypotonic buffer (10mM Tris HCl pH 7.5, 1,5 mM MgCl2, 10 mM 
KCl, 0,1 mM EDTA, 1X PIC) and incubated on ice for 8 min. ¼ of lysate was conserved 
as total extract and cytoplasmic fraction was separated from nuclei by centrifugation at 
1000g for 5 min at 4°C. The resulting pellet, enriched in nuclei, was washed in hypotonic 
buffer, kept on ice for 5 min to better purify the nuclear fraction. Nuclei were pelleted at 
1000g for 5 min at 4°C, resuspendend in nuclear lysis buffer (50mM Tris HCl pH8, 150 
mM NaCl, 2mM EDTA, 1% Triton X-100, 1mM DTT, 1X PIC) and incubated on ice for 
30 min. Subsequently, genomic DNA was destroyed by sonication and cellular debris 
removed by centrifugation at 14000 rpm for 15 min. The same volume of total extracts, 
cytoplasmic and nuclear fractions (correspondent to the same number of cells) was 
separated by SDS-PAGE. Subcellular distribution was calculated dividing the signal 
revealed in the nuclear fraction by the one of the cytoplasmic fraction and normalized to 
control samples arbitrarily set to 1.0.  
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5.8 Primary neuronal cell cultures 
 
Primary cortical cultures were obtained from WT and CDKL5 knockout (Cdkl5Y/-) [65] 
brains of mouse embryos at 15 days (E15) obtained by crossing heterozygous females 
(Cdkl5+/-) [65] with WT males (Charles River Laboratories). Mice were sacrificed by 
cervical decapitation and embryo brains were removed under a microscope. Embryos 
were genotyped by PCR on genomic DNA as described by Fuchs et al. [77]. Cerebral 
cortex was rapidly dissected and maintained in cold 1X HBSS.  After washes with 1X 
HBSS, cortices were digested with 0.25% Trypsin/EDTA (Life Technologies) by 7 min 
of incubation at 37°C. Trypsin was eliminated and inactivated by washing with 1X HBSS 
and then with a Neurobasal medium containing 10% FBS (Gibco), 2% B27 (Gibco), 1% 
L-glutamine (Sigma Aldrich), 0.5% penicillin/streptomycin (Sigma Aldrich).  By gentle 
pipetting, cells were dissociated and counted in a Bürker chamber after dilution in 0.4% 
Trypan Blue. Dissociated neurons were diluted in Neurobasal medium supplemented with 
10% FBS, 2% B27, 1% L-glutamine and 0.5% penicillin/streptomycin, plated on coated 
slides (1 mg/ml poly-L-lysine hydrobromide) in 24-well dishes (70000 cells/well) and 
maintained at 37°C with 5% CO2. Two hrs later, medium was removed and replaced with 
the definitive medium composed by Neurobasal supplemented with 2% B27, 1% L-
glutamine. At DIV12 cortical neurons were transfected using calcium phosphate method 
(2µg DNA/well) and 500 µg/ml G418 was administered 24 hrs later. At DIV14 neurons 
were fixed for 15 min in 4% PFA at room temperature and analysed by IF. 
 
5.8.1 Morphological analysis. 
Morphological analyses were performed on cortical CDKL5-null neurons at DIV14. 
IF was performed as described using a chicken anti-GFP (1:500) and DAPI (1:1000 in 
1X PBS). GFP positive neurons were acquired using a NikonEclipse Ni upright 
microscope at 40X magnification; neuronal branching was evaluated defining the 
following parameters: £ 5 branches: low branching; 6-11 branches: intermediate 
branching; >11 branches: high branching. 
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5.8.2 3-(4,5-dimethylthiazol-2-yl)2-5-diphenyltetrazolium bromide 
(MTT) assay 
 
WT cortical neurons were plated in 96 well dishes (10000 cells/well) and cultured in 
Neurobasal supplemented with 2% B27, 1% L-glutamine without penicillin and 
streptomycin. At DIV12 cortical neurons were treated with different doses of G418 (100, 
200, 300, 500 µg/ml) or vehicle (1X PBS, untreated); G418 was dissolved in Neurobasal 
supplemented with 2% B27, 1% L-glutamine. 24 hrs later, neurons were incubated with 
0.4 mg/ml of MTT (Sigma, 5655) at 37°C with 5% CO2 for 4 hrs. Thereafter the medium 
was aspirated, wells were allowed to dry and 100 µl of a solution containing HCl 1:25 in 
isopropanol was added to each well. After formazan had dissolved, the absorbance was 
determined at 540 nm using a spectrophotometer (Wallac 1420 VICTOR2TM; Perkin 
Elmer). Cell viability was evaluated dividing the mean of absorbance values of treated 
sample by the one of untreated neurons. 
 
5.9 Statistical analysis 
 
All values are expressed as means ± standard error (SEM). The significance of results 
was evaluated by Student's t test, one way or two-way ANOVA followed by Bonferroni’s 
post hoc test using Prism software (GraphPad Software, Inc. La Jolla CA, USA). 
Statistical significance was established as p < 0.05.  
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CDKL5 localizes at the centrosome 
and midbody and is required for 
faithful cell division
Isabella Barbiero1, Davide Valente2, Chetan Chandola  1,5, Fiorenza Magi3,6, Anna Bergo1, 
Laura Monteonofrio2, Marco Tramarin1, Maria Fazzari4, Silvia Soddu2, Nicoletta Landsberger4, 
Cinzia Rinaldo2,3 & Charlotte Kilstrup-Nielsen  1
The cyclin-dependent kinase-like 5 (CDKL5) gene has been associated with rare neurodevelopmental 
disorders characterized by the early onset of seizures and intellectual disability. The CDKL5 protein 
is widely expressed in most tissues and cells with both nuclear and cytoplasmic localization. In 
post-mitotic neurons CDKL5 is mainly involved in dendritic arborization, axon outgrowth, and 
spine formation while in proliferating cells its function is still largely unknown. Here, we report that 
CDKL5 localizes at the centrosome and at the midbody in proliferating cells. Acute inactivation of 
CDKL5 by RNA interference (RNAi) leads to multipolar spindle formation, cytokinesis failure and 
centrosome accumulation. At the molecular level, we observed that, among the several midbody 
components we analyzed, midbodies of CDKL5-depleted cells were devoid of HIPK2 and its cytokinesis 
target, the extrachromosomal histone H2B phosphorylated at S14. Of relevance, expression of the 
phosphomimetic mutant H2B-S14D, which is capable of overcoming cytokinesis failure in HIPK2-
defective cells, was sufficient to rescue spindle multipolarity in CDKL5-depleted cells. Taken together, 
these results highlight a hitherto unknown role of CDKL5 in regulating faithful cell division by 
guaranteeing proper HIPK2/H2B functions at the midbody.
CDKL5 is a serine-threonine kinase that was identified through a transcriptional mapping study aimed at iden-
tifying disease causing genes in the Xp22 region1. The subsequent identification of mutations in the CDKL5 
gene in patients with the Hanefeld variant of Rett syndrome or early infantile epileptic encephalopathy (OMIM 
#300672) suggested the involvement of this gene in human brain functions2. In agreement, the two existing Cdkl5 
knock-out mouse models are characterized by impaired learning and memory, autistic-like features, and motor 
deficits reconciling several aspects of the clinical spectrum present in patients with mutations in CDKL53, 4.
The CDKL5/Cdkl5 gene is widely transcribed and the protein can be detected in most tissues and cells, both in 
the nucleus and in the cytoplasm5, 6. However, CDKL5 expression reaches highest levels in the brain6 and because 
of the evident brain-associated functions, most studies have focused on the neuronal roles of CDKL5. In the brain 
CDKL5 expression is low at embryonic stages but a significant induction can be observed in the neuronal com-
partment in the first post-natal days supporting a role during neuronal maturation5. In post-mitotic neurons the 
levels and distribution of CDKL5 are regulated by neuronal activity indicating that the protein responds promptly 
to external stimuli7, 8. Of relevance, neurons devoid of the kinase are characterized by defects in axon formation 
and outgrowth, dendritic arborization, spine morphology, and synaptic transmission, underscoring the impor-
tance of CDKL5 for brain development and functioning4, 6, 9, 10.
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While the functions of CDKL5 in post-mitotic neurons are under continuous investigation, its role in pro-
liferating cells is still largely unknown. CDKL5 overexpression induces cell cycle arrest in neuroblastoma cells11 
whereas CDKL5 inhibition, by RNAi or targeted gene disruption, was shown to increase bromodexoyuridine 
incorporation11, 12. Although these data suggest the involvement of CDKL5 in cell proliferation, no information is 
available regarding the functions and the subcellular localization of the kinase during the cell cycle. In the current 
study we examined the localization of CDKL5 in interphase, mitosis, and cytokinesis of proliferating cells. Besides 
the typical nuclear punctuate staining of CDKL5 in interphase cells13, we also found CDKL5 to be localized at the 
centrosomes and at the midbody.
In animal cells, centrosomes form when a pair of orthogonally positioned centrioles assemble and organize a 
matrix of proteinaceous pericentriolar material around themselves. Centrioles act as the centrosome organizer 
and their duplication controls centrosome number. Like DNA, centrioles duplicate semi-conservatively exactly 
once per cell cycle14. The centrosome serves as the main microtubule-organizing center that contributes to cell 
adhesion, motility, and polarity in interphase and to bipolar spindle formation and timely mitotic progression in 
mitosis15, 16. During mitosis, the presence of two centrosomes per cell ensures the bipolar nature of the spindle 
and the equal segregation of chromosomes to two daughter cells. Quantitative or qualitative centrosome defects 
may lead to multipolar spindle formation and, eventually, loss of mitotic fidelity and acquisition of chromosome 
instability17, 18.
The midbody is the narrow intercellular bridge containing bundles of microtubules derived from the mitotic 
spindle that connects the two daughter cells in cytokinesis. A complex network of components impacting on ves-
icle and membrane trafficking, cytoskeleton, chromosomes, cell cycle and lipid rafts affects midbody formation 
and cleavage19. Among the numerous midbody components, we have shown that HIPK2, an evolutionary con-
served kinase whose large number of substrates includes the Rett syndrome associated factor MeCP220, localizes 
at the midbody and is required for faithful cytokinesis21. HIPK2 contributes to abscission, the last step of cell divi-
sion, by phosphorylating extrachromosomal histone H2B at serine 14 (S14) at the midbody. In HIPK2-defective 
cells, expression of a phosphomimetic H2B-S14D mutant overcomes the cytokinesis failure21.
By biochemical and functional assays, we confirmed the presence of CDKL5 both at centrosomes and at 
the midbody and highlighted the involvement of CDKL5 in cell division through the regulation of HIPK2/H2B 
functions.
Results
CDKL5 localizes at the centrosome and midbody. To investigate the function(s) of the ubiquitously 
expressed CDKL5 in proliferating cells we started evaluating the subcellular localization of the kinase during 
the cell cycle. The distribution of endogenous CDKL5 was analyzed in HeLa cells by immunofluorescence (IF) 
during interphase, mitosis, and cytokinesis (Fig. 1). We observed a quite dynamic localization of CDKL5 at dif-
ferent mitotic and cytokinetic subcompartments. In prophase and metaphase, CDKL5 is detectable at the mitotic 
spindle poles where it colocalizes with the centrosomal marker γ-tubulin. As cells progress in telophase, CDKL5 
is no longer detectable at the centrosome but localizes at the midzone. In the subsequent steps of cytokinesis 
Figure 1. CDKL5 localizes at the centrosome and at the midbody in proliferating cells. HeLa cells were stained 
with Abs against CDKL5 (polyclonal, green) and γ-tubulin (red) and, to visualize DNA, with DAPI (blue). Scale 
bar, 10 µm.
www.nature.com/scientificreports/
3Scientific RepoRts | 7: 6228  | DOI:10.1038/s41598-017-05875-z
CDKL5 is clearly detectable at the midbody, where it remains during abscission. As expected, in interphase we 
observed the typical punctuate nuclear staining of CDKL5, which corresponds to nuclear speckles enriched in 
mRNA splicing factors13.
Next, through additional studies we validated the centrosomal and midbody localization of CDKL5 suggested 
by the above IF results.
Regarding the centrosomal localization, we confirmed the overlapping staining of CDKL5 and γ-tubulin in 
different cells, such as SV40-transformed COS7 cells and human fibroblasts, MRC-5 (Fig. 2a). In the latter cells, 
the centrosomal localization of CDKL5 could be detected also in interphase by using two different antibodies 
(Abs) (Supplementary Fig. S1a,b). The specificity of the result was further confirmed through siRNA mediated 
silencing of CDKL5, which led to a significant reduction of the centrosomal CDKL5 staining (Supplementary 
Fig. S1b,c). Similar to endogenous CDKL5, exogenous green fluorescent protein (GFP)-tagged CDKL5 can be 
detected at the centrosome in metaphase cells (Fig. 2b). Finally, the presence of CDKL5 at the centrosome was 
verified by biochemical fractionation of centrosomal proteins obtained from nocodazole/cytochalasin B-treated 
HeLa cells transfected with a CDKL5 specific siRNA (siCDKL5) or the relative control (siCtr). Western blot (WB) 
Figure 2. CDKL5 is localized at the centrosome. (a) The indicated cells were stained as in Fig. 1. (b) 
Exogenously expressed GFP-CDKL5 (green) localizes at the γ-tubulin positive (red) centrosome in HeLa 
cells. DAPI staining (blue) was used to visualize DNA. (c) HeLa cells were transfected with siCDKL5#1 or a 
control siRNA (siCtr.); centrosomes were purified 60 h post-transfection and the obtained fractions analyzed 
by WB with Abs against CDKL5 and γ-tubulin. Input corresponds to approximately 0.6% of the whole cell 
extract before fractionation. Fractions 1 and 6 are the bottom and top ones, respectively (n = 3 independent 
experiments). Input and fractions 1–6 are shown as different exposures of the same membrane; full-length 
blots are presented in Supplementary Figure S7a. (d) Neurospheres (upper) and primary hippocampal neurons 
(DIV4; lower) were stained with Abs against CDKL5 (polyclonal, green) and either γ-tubulin or pericentrin 
(both red) and DAPI (blue). The panels to the right show the magnified centrosome. Scale bar, 10 µm.
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analyses show the presence of endogenous CDKL5 in the γ-tubulin positive centrosomal fractions from siCtr cells 
but not from siCDKL5 cells (Fig. 2c). Considering the importance of the centrosome for neuronal functions, we 
also analyzed whether CDKL5 is present at the centrosome in cultured neuronal progenitors and post-mitotic 
primary hippocampal neurons. Interestingly, CDKL5 is detectable at the centrosome in both cell types (Fig. 2d).
To validate the midbody localization, we first performed IF to confirm the co-staining of CDKL5 with two 
midbody markers, α-tubulin and PLK-122 in different cell types using two different anti-CDKL5 Abs (Fig. 3a 
and Supplementary Figure S2). As above, the specificity of the Ab was tested by silencing CDKL5 expression 
in HeLa cells (Fig. 3b). As biochemical approach, we isolated and purified midbodies from proliferating HeLa 
cells enriched in telophase by nocodazole treatment, mitotic shake off, and release after nocodazole washout21. 
Successful midbody isolation was assessed by IF (Fig. 3c, lower panel). Midbody extracts (MID) were analyzed by 
WB and compared with total cell extracts (TCE) from the same number of cells in interphase (TCE-I) and telo-
phase (TCE-T). WB for the mitotic kinases Aurora A and cytoplasmic AKT was used to validate the fractionation 
protocol. In line with the results obtained by IF, endogenous CDKL5 can be detected in the midbody extracts 
both by WB (Fig. 3c) and by immunoprecipitation (Fig. 3d). Finally, similar to endogenous CDKL5, exogenous 
GFP-CDKL5 is detectable at the midbody by IF (Fig. 3e) and in midbody extracts by WB (Fig. 3f).
Altogether, these results show that, beside its well-defined nuclear and cytoplasmic localization, CDKL5 also 
localizes at the centrosome and midbody in different cell types.
CDKL5 depletion triggers mitotic spindle multipolarity by centrosome accumulation. We then 
evaluated the phenotype of CDKL5-depleted cells during cell division. IF analyses were performed with HeLa 
cells 60 h after siRNA transfection when CDKL5 expression is strongly reduced (Fig. 4a). Compared with siCtr, 
siCDKL5 HeLa cells showed a significant increase in the number of cells with multipolar spindles (Fig. 4b) asso-
ciated with different chromosome segregation defects including anaphase/telophase chromosome bridges, micro-
nucleation, and binucleated cells (Fig. 4c). In addition, a significant increase in the number of cells positive for 
the mitotic marker phosphorylated histone H3-S10 (Fig. 4d) supported that an increased number of cells accu-
mulate in mitosis. Similar defects were observed also in siCDKL5 MRC-5 cells (Supplementary Figure S3). To 
exclude that the observed phenotypes were due to off-target effects, we performed rescue experiments in which 
siRNA-resistant CDKL5 was co-expressed with GFP from a bicistronic cassette in silenced HeLa cells. As shown 
in Fig. 4e–g, cells re-expressing CDKL5 have a percentage of multipolar spindles similar to siCtr cells expressing 
only GFP.
Spindle multipolarity can be due to defects in microtubule (MT) dynamics or to numeral and structural cen-
trosome alterations23. To assess the underlying cause of multipolarity in CDKL5 depleted cells, we first evaluated 
whether silencing of CDKL5 impairs MT dynamics in COS7 and MRC-5 cells by analyzing the regrowth of MTs 
after their nocodazole mediated disruption. No significant difference was observed in the aster size of newly 
formed MTs between siCtr and siCDKL5 cells, suggesting that CDKL5 depletion does not alter the microtubule 
nucleation activity of these cells (Supplementary Figure S4).
We proceeded evaluating whether CDKL5 depletion might lead to loss of centrosome integrity. Microscopy 
analyses of siCDKL5 HeLa cells revealed a large number of mitotic spindles with more than two centrosomes, 
that appear grossly normal, as shown by the staining with the centriolar marker centrin-2 (i.e., each centrosome 
presents two spots of centrin-2; Fig. 5a and Supplementary Figure S5). Notably, we never observed either one 
centrin-2 dot per spindle pole or a centrin-2 negative spindle pole (i.e., zero out of 140 spindles); we thus excluded 
loss of centriole cohesion or centrosome fragmentation as causative of the multipolar spindles. Furthermore, a 
significant increase of interphase cells with supernumerary centrioles (more than four per cell) was detected in 
siCDKL5 compared to siCtr cells (Fig. 5b). Altogether, these data support the hypothesis that spindle multipolar-
ity might be due to supernumerary centrosomes rather than to the loss of structural centrosome integrity.
Supernumerary centrosomes can arise through centriole overduplication or accumulation24. To distinguish 
between these two events, double IF analysis for centrin-2 and Cep170 was performed25, 26. Cep170, a marker for 
mature, maternal centrioles, can be used to assess the ratio of mature, maternal centrioles and immature, daugh-
ter centrioles. This ratio is balanced during centrosome accumulation whilst centrosome duplication causes an 
excessive number of daughter centrioles compared to maternal ones. Quantification of the Cep170 and centrin-2 
staining revealed that CDKL5-deficient cells show a significant increase in centriole accumulation compared to 
siCtr cells whereas no significant difference was observed in centriole overduplication (Fig. 5c).
Taken together, these results indicate that CDKL5 depletion triggers mitotic spindle multipolarity through 
centrosome accumulation.
CDKL5 depleted cells show polyploidization and cytokinesis failure. Centrosome accumulation 
can originate via different pathways, including endoreduplication, mitotic slippage (mitosis without chromosome 
segregation), cytokinesis failure, and cell fusion24. We thus analyzed siCDKL5 cells by in vivo time-lapse imag-
ing. Compared to controls, siCDKL5 cells show a significantly longer prometaphase time [from the round-up to 
chromosome segregation; t = 148.3 ± 91.34 min in siCDKL5 (n = 74) versus 59.07 ± 33.64 min in siCtr (n = 73); 
p < 0.001]. In these cells, we also observed a significantly longer cytokinesis time [from the cleavage furrow 
ingression to cell daughter separation; t = mean ± Standard deviation = 186.38 ± 78.39 min in siCDKL5 (n = 66) 
versus 139.81 ± 62.81 min in siCtr (n = 62); p < 0.001] and cytokinesis failure resulting in the formation of binu-
cleated cells (Fig. 6a,b and Supplementary Movies S1, S2 and S3). We did not observe any sign of cell death or 
mitotic slippage (i.e. no cells that, after round-up, re-adhere without chromosome segregation) in either siCtr or 
siCDKL5 cells during the imaging session (Fig. 6a,b, Supplementary Movies S1 and S2 data not shown).
Altogether, these findings show that CDKL5 depletion leads to polyploidization and cytokinesis failure.
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CDKL5 depletion impairs HIPK2/H2B midbody activity. The midbody localization of CDKL5, the 
longer cytokinesis time, and the increment of binucleated cells upon silencing of CDKL5 (Figs 4c and 6a,b and 
Supplementary Figure S3c) support the hypothesis that depletion of the kinase might affect cytokinesis. Thus, 
to get insight into the molecular mechanism involved in the observed cytokinesis failure, we evaluated whether 
Figure 3. CDKL5 localizes at the midbody. (a) The indicated cells were immunostained with Abs against 
CDKL5 (polyclonal, green) and α-tubulin or PLK-1 (red) to mark the midbody. DAPI staining (blue) was 
used to visualize DNA. Arrows indicate the CDKL5 positive midbodies, shown enlarged in the lower panels. 
(b) HeLa cells were treated as in Fig. 2c and silencing of CDKL5 expression was verified by western blotting 
60 h post siRNA transfection (left). Immunofluorescence analysis (right) showed that only 53.5% ± 5.65 of 
siCDKL5-treated cells were positive for staining with CDKL5 Ab (polyclonal) at the midbody as opposed to 
97.5% ± 2.12 of siCtr cells (n = 2; **p < 0.01; unpaired t-test; 160 midbodies analyzed per condition). Scale bar, 
5 µm. (c) Total cell extracts of interphase (TCE-I) and telophase (TCE-T) cells were analyzed by WB together 
with extracts of purified midbodies (MID) with the indicated Abs. Midbody isolation was confirmed by 
immunofluorescence with Abs against CDKL5 and α-tubulin before extraction (lower panel), (n = 3). (d) WB 
showing immunoprecipitation of a midbody protein extract with polyclonal anti-CDKL5 or anti-IgG. Input 
corresponds to 10% of the midbody extract before the immunoprecipitation. (n = 2). (e) Exogenously expressed 
GFP-CDKL5 (green) could be detected at the midbody in transfected Hela cells. Arrows indicate GFP-CDKL5 
at the midbody. Right panels show the magnified midbody. (f) Midbodies (MID) were purified from HeLa 
cells expressing GFP or GFP-CDKL5 and the extracted proteins were analyzed by WB with the indicated Abs 
together with an interphase total cell extract (TCE-I) (n = 2). Scale bars in a and e, 10 µm.
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CDKL5-depleted cells show any midbody defects. The localization of different structural and functional mid-
body factors including kinases (i.e., Aurora B, PLK1, HIPK2) and microtubule-associated proteins (i.e., MKLP1, 
MgcRacGap1, PRC1, and Spastin)21, 22, 27, 28 were assessed by IF in siCtr and siCDKL5 HeLa cells. Among the 
Figure 4. Silencing of CDKL5 is associated with multipolar spindle formation and chromosome segregation 
defects. (a) CDKL5 expression in HeLa cells 60 h after transfection with two different siRNAs targeting CDKL5 
or a control siRNA. α-tubulin was used as loading control. The asterisk indicates an unspecific band (b,c) 
HeLa cells treated as in a were stained against α-tubulin and DAPI 60 h post-transfection. In b, the percentage 
of mitotic multipolar spindles is reported as mean ± S.E.M. (n = 3; *p < 0.05, ANOVA followed by Dunnet’s 
post hoc analysis). In c, the frequency of the indicated phenotypes is shown as mean ± S.E.M. (n = 2; *p < 0.05; 
**p < 0.01; unpaired t-test; approximately 1000 counted cells per condition). In b and c, representative images 
of the indicated cells are shown above the graphs with DAPI in blue and α-tubulin in red; scale bar, 10 µm. In c, 
arrows indicate a chromosome bridge and micronuclei. A/T = ana-/telo-phase. (d) HeLa cells were treated as in 
a and analyzed for phosphorylated histone H3 (P-H3) 60 h after silencing. The percentage of P-H3 positive cells 
was calculated in three independent experiments counting approximately 2000 cells (mean ± S.E.M., unpaired 
t-test). (e) CDKL5 was expressed in HeLa cells 60 h post-silencing by transfection of a bicistronic vector 
expressing also GFP. Vertical cropping was performed to show different exposures of the same membrane; full-
length blots are shown in Supplementary Figure S7b. (f) Representative images of spindles in GFP-positive cells 
(green) treated as in e by staining against α-tubulin (red) and with DAPI (blue). Scale bar, 10 µm. (g) Graph 
showing number of cells with multipolar spindles upon CDKL5 re-expression in silenced cells. ≥ 60 counted 
cells per condition (n = 3; mean ± S.E.M, *p < 0.05; ANOVA followed by Dunnet’s post hoc analysis). n.s. = not 
statistically significant.
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analyzed factors, we found only HIPK2 to be absent from the midbody in a high percentage of siCDKL5 cells com-
pared with the siCtr cells (Fig. 6c and Supplementary Figure S6). HIPK2 contributes to cytokinesis through the 
phosphorylation of extrachromosomal histone H2B at S14 at the midbody21. Thus, using a phospho-specific Ab 
we analyzed the presence of phosphorylated H2B-S14 at the midbody in cells silenced for CDKL5. Consistently 
with the delocalization of HIPK2, we did not detect any phosphorylation of H2B-S14 at the midbody in a high 
percentage of CDKL5-depleted cells (Fig. 6d) suggesting that CDKL5 contributes to cytokinesis by regulating 
HIPK2/H2B activity at the midbody.
The most evident phenotype we have observed in the CDKL5 depleted cells is spindle multipolarity, which 
we linked to polyploidization and centrosome accumulation. Moreover, we observed a cytokinesis failure that 
is known to depend on HIPK2/H2B activities at the midbody. Thus, we hypothesized that loss of HIPK2 and 
H2B-S14 phosphorylation at the midbody might trigger a cascade of events starting from cytokinesis failure 
leading to centrosome accumulation and the formation of multipolar spindles. We thus asked whether spin-
dle multipolarity in siCDKL5 HeLa cells could be rescued by the expression of a phosphomimetic H2B-S14D 
derivative, which was previously shown to be capable of overcoming cytokinesis failure in HIPK2-defective 
cells21. As shown in Fig. 6e, the expression of H2B-S14D significantly reduced the number of cells with multipo-
lar spindles in siCDKL5 cells indicating that CDKL5 contributes to cytokinesis through HIPK2-mediated H2B 
phosphorylation.
Discussion
In the last ten years genetic lesions in CDKL5 have been found in patients with neurologic disorders characterized 
by the early onset of often intractable seizures, intellectual disability, and impaired motor control2. Given the huge 
Figure 5. Spindle multipolarity in CDKL5 depleted cells is due to centrosome accumulation. (a–c) HeLa cells 
were silenced as in Fig. 4a and analyzed by IF 60 h after transfection. In (a) cells were stained with Abs anti-γ-
tubulin and anti-centrin-2 to mark the spindle poles and the centrioles, respectively. DAPI staining (blue) was 
used to visualize DNA. The insets below show the magnified centrin-2 signal in the correspondingly numbered 
poles. The percentage of spindles with supernumerary centrosomes is reported to the right as mean ± S.E.M. 
(n = 2; *p < 0.05; unpaired t-test; approximately 70 spindles were analyzed per condition). In (b) cells were 
immunostained with centrin-2 and the percentage of interphase cells with more than 4 centrioles was reported 
as mean ± S.E.M. (n = 3; *p < 0.05; unpaired t-test; approximately 100 cells were analyzed per condition). In 
c cells were stained with anti-cep170 (green) and anti-centrin-2 (red) Abs. DAPI staining (blue) was used to 
visualize DNA. Representative images of different siCDKL5 phenotypes are shown on the left. The percentage 
of cells with the indicated phenotypes is reported to the right as mean ± S.E.M (n = 2; *p < 0.05; unpaired t-test; 
approximately 200 cells were analyzed per condition). n.s. = not significant. Scale bar, 10 µm.
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repercussion of CDKL5 mutations on brain functions, most studies have so far focused on the role of this kinase 
in neurons and very few pieces of information are yet available regarding its role in proliferating cells. Few data 
have suggested that CDKL5 is involved in cell proliferation11, 12, but the subcellular localization and the function 
of this kinase during the cell cycle are still missing.
Here we present evidence that CDKL5 contributes to faithful cell division. Indeed, we found that the acute 
ablation of CDKL5 leads to multipolar spindle formation and cytokinesis failure in HeLa and in MRC-5 cells. 
The increase in the duration of prometaphase and the presence of micronucleated cells suggest that chromosome 
segregation occurs with reduced fidelity in these cells and that genome instability might be linked to CDKL5 
dysfunctions. Therefore, it might be relevant to investigate further genome stability in Cdkl5-null or defective 
backgrounds.
In accordance with a role of CDKL5 in cell division, we observed that its subcellular localization is highly 
dynamic throughout mitosis and cytokinesis. Indeed, we found an accumulation of CDKL5 at the centrosome 
from prophase to anaphase and at the midbody in cytokinesis. Among the various midbody factors that we 
analyzed, only HIPK2 was absent from the midbody in CDKL5 depleted cells. The concomitant reduction of 
phosphorylated H2B at the midbody and the capacity of the phospho-mimetic H2B-S14D to rescue multipolarity 
in CDKL5 deficient cells suggest a causative link between the midbody defects and the aberrant mitotic spindles. 
This is reinforced by the increased number of centrosomes that appear to arise through accumulation rather 
Figure 6. CDKL5 depletion is associated with cytokinesis failure and impaired HIPK2/H2B activity. (a) 
Indicated HeLa cells were analyzed 60 h post-silencing by time-lapse videomicroscopy. The duration of 
prometaphase and cytokinesis is reported in box plot graphs (***p < 0.001, unpaired t test). (b) Still images 
related to Supplementary Movies S1, S2 and S3, respectively upper, middle and lower panels. Representative 
still images of siCDKL5 cells with very long cytokinesis time (middle panels) and of siCDKL5 cells that fail 
cytokinesis and form binucleated cell (lower panels) are showed. Time is indicated in minutes. Scale bar, 
10 µm. (c, d) Midbody localization of HIPK2 (c) and H2B phosphorylated at S14 (d; H2B-S14P) was analyzed 
in the indicated HeLa cells 60 h post-silencing by staining with Abs against α–tubulin (red) and HIPK2/
H2B-S14P (green) and with DAPI (blue). The percentage of cells with HIPK2/ H2B-S14P negative midbodies 
is indicated for each condition (n = 2; mean ± S.E.M., *p < 0.05; **p < 0.01 unpaired t-test; approximately 80 
midbodies were analyzed per condition). Scale bar, 10 µm. (e) Graph showing percentage of multipolar spindles 
in siCDKL5 cells expressing GFP-H2B WT or GFP-H2B-S14D 48 and 72 h after siRNA transfection (n = 2; 
*p < 0.05; unpaired t-test; approximately 80 cells were analyzed per condition). WB showing CDKL5 and GFP-
H2B protein levels 72 h after siRNA transfection is reported.
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than through centrosome duplication defects and by the observation that multipolarity appears to be strictly 
associated with polyploidy after CDKL5 depletion in the diploid MRC-5 cells (Supplementary Figure S3d and e). 
Even if further studies are warranted to explore the precise mechanism through which CDKL5 depletion leads to 
the midbody deprivation of HIPK2, our results highlight a novel function of CDKL5 in cytokinesis through the 
regulation of HIPK2/H2B at the midbody.
At this point, we cannot ruled out that CDKL5 has additional roles in early mitotic stages (prometaphase and 
metaphase). Indeed, the longer prometaphase time (Fig. 6a,b) and the higher frequency of chromosome bridges 
and micronuclei compared to the reduced number of binucleated cells (Fig. 4c) that we observed in siCDKL5 
cells suggest that CDKL5 depletion might also induce defects in chromosome alignment and/or segregation. Such 
defects cannot only be linked to midbody alterations.
Conversely, we do not observe any apparent structural centrosome defects in CDKL5 deficient cells. However, 
this does not preclude the existence of centrosome-associated CDKL5 functions that may emerge from further 
studies. Interestingly, it is to note that the large group of proteins that have been functionally linked to the cen-
trosome includes MeCP229, the main cause of Rett syndrome and an interactor and in vitro substrate of CDKL530, 
31. Whether a cross-talk between CDKL5 and MeCP2 exists at the centrosome still remains to be understood. Of 
note, the reduced MT nucleation capacity of centrosomes in MeCP2 deficient cells, but not in cells silenced for 
CDKL5, indicate that the two proteins have at least some separate functions in this organelle29.
Previous loss- and gain-of-function studies in SH-SY5Y neuroblastoma cells suggested that CDKL5 inhibits 
cell proliferation11. In agreement, in the developing mouse brain, genetic inactivation of Cdkl5 increases BrdU and 
Ki67 positivity12. Even if we observed an increased positivity for phosphorylated H3-S10 in our CDKL5-depleted 
cells, we did not find any increase in cell proliferation (data not shown), suggesting that the phospho-H3 positiv-
ity might be due to a prolonged cell division time. Our results, showing a role of CDKL5 in cell division, suggest 
that the influence of CDKL5 on cell proliferation might be linked to its effects on genome stability. This would be 
in agreement with the observation made in neuroblastoma patients, in which high expression of CDKL5 corre-
lates with an increased overall survival11. However, the action of CDKL5 in tumorigenicity is definitively more 
complex since, at variance with neuroblastomas, in glioblastomas, CDKL5 was shown to be required for tumor 
cell survival and increased CDKL5 expression was found to be associated with reduced overall survival32. Future 
studies will be essential to investigate the role of CDKL5 in tumorigenesis.
Although defects in CDKL5 have mainly been associated with a neurological disease we consider likely that its 
influence on cell cycle progression may be of relevance also in the pathology. In fact, it is well known that the pre-
cise control of the cell cycle critically regulates neurogenesis, neuronal differentiation and migration33 and defects 
in neuronal progenitor proliferation and differentiation seem to be a convergence point in many neurodevelop-
mental disorders34. Of interest, defects in centrosomal proteins are known to impinge on neuronal migration and 
axon formation35. We thus speculate that the defects in radial neuronal migration and axon specification that have 
previously been associated with CDKL5 knock-down may be linked to a function of CDKL5 at this organelle6, 9. 
Altogether, a further understanding of the precise role of CDKL5 in cell cycle progression and at the centrosome 
might be relevant to recognize the origin of some features of the human pathology associated with CDKL5.
Materials and Methods
Ethics Statement. Protocols and use of animals were approved by the Animal Ethics Committee of the 
University of Insubria and in accordance with the guidelines released by the Italian Ministry of Health. Adult 
mice were euthanized by cervical dislocation.
Plasmids. pGFP-CDKL5, expressing the 107 kDa hCDKL5 isoform has been described else-
where36. pCAGGS-CDKL5-ires-GFP, expressing a siRNA resistant form of CDKL5, was cloned by insert-
ing an EcoRI-EcoRV digested PCR product containing the murine CDKL5 cDNA (NP_0010795) into 
pCAGGS-ires-GFP digested with EcoRI and SmaI. siRNA resistant CDKL5 contains three nucleotide changes 
in the third position of codons 25–27 (ggagttgra =  > ggcggagtt). pBosH2B-GFP and pBosH2BS14D-GFP have 
been described in Rinaldo et al.21.
Antibodies. Antibodies (Abs) against the following proteins were used: β-actin (Sigma-Aldrich, St Louis, MO, 
USA, A5441), α-tubulin (Sigma-Aldrich, T6074), β-tubulin (Sigma-Aldrich, C4585), γ-tubulin (Sigma-Aldrich, 
T5326), CDKL5 (polyclonal, Sigma-Aldrich, HPA002847; monoclonal Santa Cruz, clone D-12, sc-376314), 
AKT (Cell Signaling, 4685), Aurora kinase A (Sigma-Aldrich, A1231, clone 35C1), GFP (Roche Diagnostics Ltd, 
1814460), PLK-1 (Santa Cruz, sc-17783), phospho-H3-S10 (Abcam, ab14955), H2SB14-P (Cell Signaling, 6959); 
centrin-2 (Santa Cruz, sc-27793), Cep170 (ThermoFisher Scientific, 41-3200) and HIPK2 (rabbit polyclonal21); 
MgcRacGAP1 (Abcam, ab2270), MKLP1 (Santa Cruz; sc-22793); PRC1 (Santa Cruz, Sc-8356); spastin (Santa 
Cruz, Sc-53443), CREST centromere protein (Antibodies Inc., 15-234-0001). HRP-conjugated goat anti-mouse or 
anti-rabbit secondary Abs for immunoblotting were purchased from Thermo Fisher Scientific. DAPI and second-
ary Alexa Fluor anti-rabbit, anti-mouse, anti-human, and anti-goat Abs for immunofluorescence were obtained 
from Life Technologies while FITC- or TRITC-conjugated Abs were from Jackson Immuno Research Lab.
Cell cultures, transfections and RNA interference. Human cervix adenocarcinoma HeLa cells, the 
monkey SV-40-transformed kidney COS7 cells, and human fetal lung fibroblasts MRC-5 cells were maintained 
in DMEM (Dulbecco’s modified Eagle’s medium; Sigma-Aldrich) supplemented with 10% FBS, L-glutamine, 100 
units/ml penicillin, and 100 µg/ml streptomycin at 37 °C with 5% CO2. Rat adrenal gland pherochromocytoma 
PC12 cells were maintained in RPMI (Gibco, Thermo Fisher Scientific) supplemented with FBS, L-glutamine, 
penicillin, and streptomycin as above; these cells were seeded on poly-D-lysine coated coverslips.
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For transfection, cells were cultured in 6- or 12-well dishes and transfected with plasmids using 
LipofectamineTM 2000 (Life Technologies) following the manufacturer’s protocol. Cells were collected or fixed 
24 h post-transfection. For siRNA transfection, 20 nM siRNA oligonucleotides targeting CDKL5 or control 
GL2 siRNA targeting the luciferase gene (shCDKL5#1: CUAUGGAGUUGUACUUAAAUU; shCDKL5#2: 
GCAGAGUCGGCACAGCUAUUU; siCtr. 5′CGUACGCGGAAUACUUCGAUU3′) were transfected into HeLa 
or MRC-5 cells using LipofectamineTM RNAiMAX (Life Technologies).
For CDKL5 rescue experiments, a siRNA resistant pCAGGS-CDKL5-ires-GFP vector was transfected 60 h 
after CDKL5 silencing and cells analyzed after another 24 h. For H2B-GFP or H2B-S14D expression, encoding 
vectors were transfected 24 h after CDKL5 silencing and cells were analyzed 24 and 48 h post-transfection.
Primary neuronal cultures. Primary hippocampal cultures were prepared from embryonic day 17 (E17) 
CD1 mouse embryos, considering the day of the vaginal plug as E0, as described previously7 and plated on 
poly-L-lysine coated plates (densities: 2,5 × 103/cm2).
Neurosphere preparation. Neurospheres were prepared as previously described37. Briefly, E15.5 embryos 
were individually dissected in PBS and the neocortex was transferred in Dulbecco’s Modified Eagle Medium/F12 
(DMEM) and dissociated by extensive enzymatic digestion with Papaine (Sigma-Aldrich). Cells were grown in 
medium containing DMEM/F12, 0.66% glucose, L-glutamine 1%, Pen/Strep 1%, 4 µg/mL of heparin, hormone 
mix with the addition of either 20 ng/mL epidermal growth factor (EGF) and 10 ng/mL basic fibroblast growth 
factor (bFGF). In such conditions, cells spontaneously formed neurospheres. Neurospheres were then dissociated 
into single-cell cultures and plated on matrigel-coated coverslips (BD Bioscience).
Centrosomal fractionation. Centrosome fractionation was performed as previously described29. Briefly, 
exponentially growing cells were treated with 10 µg/ml nocodazole and 5 µg/ml cytochalasin B (both from 
Sigma-Aldrich) for 90 min, followed by hypotonic lysis. Centrosomes were harvested by centrifugation onto a 
20% Ficoll cushion and further purified by centrifugation through a discontinuous (70%, 50% and 40%) sucrose 
gradient. Fractions of 0.3 ml were collected and analyzed by WB.
Western blotting (WB) and immunoprecipitation (IP). Cells were lysed with lysis buffer (50 mM 
Tris-HCl pH 7.5, 150 mM NaCl, 1% Triton X-100, 1 mM EDTA, 1 mM DTT) with addition of protease inhibitor 
cocktail (Sigma-Aldrich) and PhosSTOP (Roche Diagnostics). After 30 min on ice, the lysates were clarified by 
centrifugation and the supernatants collected. Samples were separated by either 10% or 8% SDS-PAGE, trans-
ferred to nitrocellulose membranes, and blocked in 5% non-fat milk in TBS (20 mM Tris-HCl, pH 7.5, 150 mM 
NaCl) with 0.2% Tween-20 (T-TBS). Blots were incubated with primary Abs overnight at 4 °C, washed in T-TBS, 
and incubated with appropriate secondary Abs for 1 h at room temperature. After extensive washes, blots were 
developed with either West PICO Chemiluminescence kit (Pierce) or with ECL Prime Western Blotting Detection 
Reagent (GE Healthcare).
Immunofluorescence (IF). Cells were grown on poly-L-lysine coated coverslips and fixed in ice-cold meth-
anol or 2% formaldehyde, washed three times in phosphate buffered saline (PBS), permeabilized in 0.25% Triton 
X-100 in PBS for 10 min and then blocked in 5% bovine serum albumin (BSA) in PBS for 1 h before the required 
primary Abs were applied. For the staining of γ-tubulin and centrosome associated proteins, cells were permea-
bilized before fixation in PHEM (60 mM Pipes, 25 mM Hepes, 10 mM EGTA, and 2 mM MgCl2) with 0.5% Triton 
X-100 for 2 min and then fixed in 4% paraformaldehyde.
Microscopy on fixed samples. For Figs 1, 2a,b,c, 3a,e and 4b,f and Supplementary Figures S2 and S3a, 
preparations were examined under a NikonEclipse Ni upright microscope equipped with a 100X (1.35 NA) 
oil immersion objective and a Nikon DIGITAL SIGHT DS-U1 CCD camera. Images were acquired using the 
NIS-Elements BR 4.13.04 software. For Supplementary Fig. S1a and S1, microscopy analysis was performed using 
a Olympus U-RFL-T microscope equipped with a 100X (1.35 NA) oil immersion objective and a Rriga R1 CCD 
camera (QImaging). Images were acquired using Ocular 1.0 software. For Supplementary Figure S4, micros-
copy was performed using a confocal laser-scanning microscope (model TCS SP8; Leica) with a 63X NA 1.2 oil 
immersion objective (Leica). Images were acquired using LAS-AF Lite software. For the Figs 3b, 4c and 6c,d and 
Supplementary S5, preparations were examined under an Olympus Vanox microscope equipped with a 100X 
(1.35 NA) oil immersion objective and a Tucsen tch-1.4ice CCD camera (Tucsen photonics co., LTD). Images 
were acquired using Isocapture 4.1.3 software (Tucsen photonics co., LTD). For Fig. 5a, microscopy was per-
formed using a Nikon Eclipse 90i microscope equipped with a oil immersion Plan Fluor 100x objective (N.A. 1.3; 
Nikon) and a Qicam Fast 1394 CCD camera (QImaging). Image acquisition, deconvolution and Extended Depth 
of Focus on z-serial optical sections were performed using Nis-Elements HC 4.2 (Nikon); Images shown were 
Maximum Intensity Projections from z-stacks.
Midbody purification. HeLa cells were enriched in telophase by treatment with nocodazole (100 ng/ml) 
for 4 h followed by mitotic shake-off. Nocodazole was washed out and the collected cells incubated for 80 min 
to reach telophase. Midbodies were isolated as described by Kuriyama et al.38 and extracted in extraction buffer 
(50 mM Tris-HCl pH 7.4, 150 mM NaCl, 0.1% SDS, 0.5% NP40, 5 mM EDTA) supplemented with protease- 
(Sigma-Aldrich) and phosphatase-inhibitors (Roche, Diagnostiics). Total cell extracts (TCE) from asynchronous 
and telophase enriched cells were analyzed in parallel.
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Live-cell imaging. Cells were seeded in 8-well slides (80826, ibiTreat) and observed under an Eclipse Ti 
inverted microscope (Nikon) using a 40x objective (Plan Fluor, N.A. 0.60, DIC, Nikon). During the observa-
tion, cells were kept in a microscope stage incubator at 37 °C and 5% CO2. DIC images were acquired by using a 
DS-Qi1Mc camera. Image and video processing were performed with NIS-Elements AR 3.22.
Statistics. For statistical analysis we assessed the normality distribution of data using the Shapiro-Wilk 
normality test: student’s t test or parametric ANOVA followed by Dunnet’s post hoc test was applied to deter-
mine the significance of quantitative experiments when the data distribution was normal. In other cases we used 
non-parametric Kruskal Wallis with Dunn’s post hoc test.
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